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Precision medicine finds a valuable ally in pharmacogenomics, which is aimed at identifying 
genetic variants involved in therapeutic response. In tailored treatments, a specific attention is 
required for those drugs showing a low therapeutic index, such as fluoropyrimidines (FL) that 
represent the backbone in the management of many types of solid tumours. FL lead to severe 
toxicity (G≥3) in a considerable percentage of patients, occasionally resulting in patients death. FL 
are mainly metabolized by dihydropyrimidine dehydrogenase (DPD; DPYD) into inactive 
metabolite. To date, only four DPYD genetic variants (DPYD *2A, DPYD *13, DPYD c.2846A>T 
and DPYD-HapB3) are known to decrease DPD activity and consequently to be associated to FL-
related toxicity. The four SNP genotyping test is recommended before a FL-based treatment by 
international shared pharmacogenetic guidelines, Despite the high specificity, this test demonstrated 
a low sensitivity, leaving the majority of the toxic events unexplained. Recently, the previously 
neglected role of novel and rare genetic variants in the intra-individual variability in the response to 
drugs has emerged. 
In this PhD thesis, we aimed at improving the knowledge on the clinical validity and clinical utility 
of the DPYD clinical diagnostic test proposed by the current pharmacogenomics guidelines, by 
investigating the impact of the four DPYD variants on fluoropyrimidines-related toxicity and costs 
for toxicity management in large cohorts of patients. In addition, we analysed the contribution of 
novel and rare genetic variants in a set of pharmaco-genes in the development of fluoropyrimidines-
related toxicity.  
Here, we show how the four-SNPs test for DPYD allow to identify a large number of patients who 
will develop severe adverse reactions to FL-based treatment in a group of 763 oncological patients.  
This is especially true if the four DPYD SNPs are arranged in the so-called gene activity score 
(GAS) weighing each SNP according to its specific impact on the DPD protein phenotype. We also 
demonstrated, in a subset of 550 colorectal cancer patients, how the DPYD genotype for the four-
SNPs set or the GAS are related to the management cost for severe toxicities related to FL.  
This finding has notable implication in the utility of the test warranting its application in the routine 
clinical practice. We subsequently analyzed, by means of a next generation sequencing approach, 
the potential role of novel or rare variants in genes in the detoxification pathway in 108 patients that 
are wild type for the well-know 4 DPYD risk variants and developed severe FL-related toxicity. We 
identified 9 rare DPYD variants, 3 were very rare missense (c.G345C, p.M115I; c.A2060C 
p.D687A and c.A2137G, p.N713D), and 6 were singleton missense (c.A110G, p.D37G; c.G481A, 





comparison, a population of 106 patients treated with a FL-based regimen, without any adverse 
reaction, displayed a depletion of novel variants (p value =0.001, by Fisher’s Exact Test). Also, as 
expected, we found a statistically significant enrichment of rare, very rare and novel exonic DPYD 
variants in the cohort of patients with severe toxicity as compared to those without (P =0.0187, P 
=0.0187, P =0.0291, respectively, by Fisher’s Exact Test). 
Despite the clinical need of tailoring treatment on each patient, to date translating the genetic 
information of each patient into a therapeutic indication remains a challenging task. The study of 
the pharmacogenomics in FL-based treatment has already provided useful and valid markers for the 
clinical practice. Therefore, we believe that the study of rare and novel genetic variants could in the 







Abstract ................................................................................................................................................. i 
Contents .............................................................................................................................................. iii 
1. Introduction ................................................................................................................................... 1 
1.1. Fluoropyrimidine ................................................................................................................... 1 
1.2. Adverse Drug Reactions (ADRs) .......................................................................................... 3 
1.3. Pharmacogenetics and pharmacogenomics ........................................................................... 4 
1.4. Pharmacoeconomy ................................................................................................................ 8 
1.5. DPYD, MTHFR and TYMS .................................................................................................... 8 
1.6. Rare Variants ....................................................................................................................... 11 
2. Rationale ..................................................................................................................................... 13 
3. Aims ............................................................................................................................................ 15 
4. Results ......................................................................................................................................... 16 
4.1 Association between DPYD genotype and FL-related DLTs .............................................. 16 
4.2. Toxicity and costs associated with its management ............................................................ 19 
4.3. Rare variants, cases cohort .................................................................................................. 23 
4.4. Rare variants distribution in the cases cohort ...................................................................... 25 
4.5. DPYD rare, very rare and novel variants ............................................................................. 29 
4.6. Rare, very rare and novel variants in FL-pathway .............................................................. 32 
4.7. Prediction tools analysis ...................................................................................................... 33 
4.8. Molecular visualization ....................................................................................................... 35 
4.9. Quantification of serum uracil and dihydrouracil concentrations ....................................... 37 
4.10. Rare variants, control cohort ............................................................................................ 37 
4.11. Rare variants distribution in the control cohort ............................................................... 38 
5. Discussion ................................................................................................................................... 44 
6. Material and Methods ................................................................................................................. 50 
6.1. Cohorts ................................................................................................................................ 50 
6.2. Data collection ..................................................................................................................... 51 
6.3. Toxicity management cost................................................................................................... 51 
6.4. DPYD Genotyping ............................................................................................................... 51 
6.4.1. Pyrosequencing ................................................................................................................ 52 
6.4.2. Allelic discrimination in real-time PCR by fluorescent-labeled probes .......................... 53 
6.4.3. Sanger Sequencing for DPYD *2A; *13; c.2846A>T, and HapB3 variants validation .. 54 
6.5. Selection of candidate genes for Next Generation Sequencing .......................................... 56 
6.6. Targeted Next Generation Sequencing................................................................................ 58 
6.7. Bioinformatic analysis ......................................................................................................... 60 
6.8. In silico functional prediction tools ..................................................................................... 60 
6.9. Sanger Sequencing to validate the DPYD variants detected by NGS ................................. 61 
6.10. Molecular visualization ................................................................................................... 62 
6.11. Quantification of serum uracil and dihydrouracil concentrations ................................... 62 
6.12. Statistical analysis ............................................................................................................ 63 
7. References ................................................................................................................................... 64 
8. Publications ................................................................................................................................. 78 
  








Since the synthesis in 1957 by Heidelberger et al. of 5-Fluorouracil (5-FU) until now 
fluoropyrimidines (FL) have become the backbone of several anti-tumour therapies.1 Fl are widely 
used for the treatment of multiple solid tumours including breast, gastrointestinal, head-neck, 
pancreatic, ovarian, skin and liver cancer.2-9  FL are a class of pyrimidine analogue, specifically 
antineoplastic antimetabolite, that include 5-FU and two inactive prodrugs capecitabine and tegafur, 
that are metabolized to 5-FU (Figure 1). 
 
Figure 1: 2D Structure of fluoropyrimidines 
 
Capecitabine and tegafur are available in oral formulation, thus they are absorbed through the gut 
wall and are converted into the active metabolite in the liver. On the contrary, 5-FU is commonly 
administered intravenously and more than 80% is metabolized in the liver by the enzyme 
dihydropyrimidine dehydrogenase (DPD; DPYD) into the inactive metabolite dihydrofluorouracil 
(DHFU), excreted in urine by kidneys catabolism.10–14 
Capecitabine (N4-pentyloxycarbonyl-5’-deoxy-5-fluorocytidine) is converted to 5-FU through a 
three enzyme cascade and the final step requires the enzyme thymidine phosphorylase (TP; 




TYMP).10 Capecitabine was designed to be highly specific for tumors cells since TP enzyme is 
significantly more active in tumor than in normal cells.10 
Tegafur (1-(2-Tetrahydrofuryl)-5-fluorouracil), a prodrug of 5-FU was developed about 50 years 
ago, is mainly activated in the liver by cytochrome P450 2A6 (CYP2A6) which hydroxylates the 
drug to 5’-hydroxitegafur, which is spontaneously dehydroxylated to 5-FU.15,16 
5-FU exhibits its anticancer activity through several mechanism. First of all, it exerts a cytotoxic 
function by a direct incorporation into the nascent DNA filament during the new DNA synthesis 
phase (S phase) of the cell cycle resulting in several DNA strand breaks.17,18 Moreover, 5-FU can be 
metabolized into fluorouridine diphosphate (FUDP) which is phosphorylated into fluorouridine 
triphosphate (FUTP) (Figure 2). As 5-FU, FUTP can be directly incorporated into RNA chain. The 
mis-incorporation of FUTP into RNA lead to: inhibition of the pre-rRNA conversion into mature 
RNA;19,20 the inhibition of polyadenylation process;21 the disruption of post-transcriptional 
modification of tRNAs;22,23 alteration of the assembly and activity of snRNA/protein complexes 
with consequences on splicing; and the post-transcriptional conversion of uridine to pseudouridine 
(Ψ).24–26 FUDP could be also converted into fluorodeoxyuridine diphosphate (FdUDP) by 
ribonucleotide reductase enzyme (RR; RRM1/2) (Figure 2). 
FdUDP can be phoshorylated or dephosphorylated into FdUTP or FdUMP, two active metabolites. 
FdUTP can be incorporated into DNA, thus inhibiting further DNA synthesis.17 An alternative 
activation pathway lead to production of FdUMP through thymidine kinase (TK; TK1) that inhibits 
thymidylate synthase (TS; TYMS) by forming a stable ternary complex.27–29 TS is an enzyme 
belonging to the folate pathway, that converts UMP to dTMP with provision of a carbon donated by 
5,10-methylene tetrahydrofolate (5,10-MTHF), the only de novo source of thymidylate, which is 
necessary for DNA replication and repair.30 Inhibition of DNA and RNA synthesis associated with 
RNA/DNA misincorporation lead to cell death.  
FL are used in different clinical setting, including adjuvant and metastatic treatment, and in 
combination with several antineoplastic drugs such as Irinotecan and Oxaliplatin or with 
monoclonal antibodies such as Cetuximab, Bevacizumab and others.31 FL showing a good efficacy 
profile are generally well tolerated, thus representing a valuable therapeutic strategy in the 
management of solid tumours. However, about 10-26% of patients treated with FL-based regimens 
develops early-onset severe or life-threatening toxicity.32,33 It is well known that pharmacokinetic 
parameters could influence the drug toxicity profile generally due to the presence of increase aging, 
chronic inflammation, oxidative stress and cellular senescence leading to an increased risk to 
develop severe toxicity, mainly in elderly patients.34 




Figure 2: Fluoropyrimidines Pathway 
 
1.2. Adverse Drug Reactions (ADRs) 
 
Edwards and Aronson defined adverse drug reaction as “an appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of a medicinal product, which predicts 
hazard from future administration and warrants prevention or specific treatment, or alteration of the 
dosage regimen, or withdrawal of the product”.35 
A careful balance between efficacy and toxicity is of primary importance in oncology due to low 
therapeutic index (TI) of the anticancer drugs. According to Common Terminology Criteria for 
Adverse Events (CTAEs) the ADRs range from mild and moderate (respectively grade 1 and 2) to 
severe, life-threatening and death (respectively grade 3, 4 and 5). The combination with other 
chemotherapeutic drugs exacerbates the appearance and grade of FL-toxicity. 
FL-related toxicity can be divided into two main groups: hematological and non-hematological 
toxicity. Hematological toxicity includes anemia, leucopenia, thrombocytopenia and neutropenia 
with a consequent increased risk of systemic infections. Non-hematological toxicity includes 
cardiotoxicity, hepatic toxicity, mucositis and stomatitis, asthenia, hand-foot syndrome, alopecia, 
nausea/vomiting and diarrhea.36 
With the high number of patients receiving FL-based therapies, and the significant effects of 
toxicities on their quality of life, it is of major clinical interest to reduce the incidence of FL-related 
adverse events. Furthermore, the adverse effects lead to an interruption of the therapy which affects 




not only the efficacy of it, but also involves an additional management cost for the national 
healthcare system.37 Indeed, adverse reactions might require the use of specific drugs, treatments 
and hospitalization with the consequence increase of management cost. 
Although fluoropyrimidines are highly used in the treatment of solid tumors, they show a high 
inter-individual heterogeneity in the response to treatment, both in terms of efficacy and in the 
development of adverse events (AEs). The high heterogeneity may depend on several factors 
including environmental, physiological and pathological factors. In a similar way to a multifactorial 
disease, environmental factors affecting the safety profile of FL include life style, smoking, diet and 
the concomitant presence of other therapies.38 Nevertheless, physiological factors such as age, sex, 
renal and hepatic function can also affect treatment response as well as pathological factors such as 
the stage and type of the disease and the concomitant presence of other diseases.38 Eventually, 
differences in human genome mainly contribute to the high heterogeneity in treatment response.39 
 
1.3. Pharmacogenetics and pharmacogenomics 
 
Pharmacogenetics, term coined by Motulsky in the 1957, describes the influence of genetic factors 
on drug therapy.40 
However, we prefer using the term pharmacogenomics (PGx), which considers the impact of 
genomics and epigenetics to the drug response, whereas pharmacogenetics does not, although the 
two terms are often used interchangeably. Pharmacogenomics, as well as personalized medicine, 
aimed at identifying genetic biomarkers. The identification of genetic biomarkers could allow the 
prevention of toxicity events and improve the effectiveness of therapy based on the genetic 
characteristics of each patient. 
Genetic biomarkers include single nucleotide variants (SNPs), accounting for the 90% of all human 
genetics variants, copy number variants (CNVs) and small or large insertion and deletion (indels).41 
Moreover, epigenetic variants and large rearrangement like deletion and inversion, can represent a 
suitable biomarker.  
Pharmacogenomics represents the present and the future of drug therapy due to the rapidly growing 
field of precision medicine.38 Pharmacogenomics screening for several drugs remains a very 
powerful, cost-effective diagnostic tool that allows clinicians to tailoring the therapy for each 
patient.  
Among the limitations of pharmacogenomics to create a clear prescription for all patients, remain 
the difficult task for clinicians in translating genetic information obtained from the pre-treatment 
laboratory tests, that is crucial to the right drug’s prescription. Clinical Pharmacogenetics 




Implementation Consortium (CPIC) and the Royal Dutch Association for the Advancement of 
Pharmacy (DPWG) aimed to overcome this barrier moving toward the clinical implementation of 
pharmacogenetics tests by creating clinical practice guidelines.42,43 Founding in the 2009 with the 
aim to create a curate, peer-reviewed guidelines, CPIC is composed by members of 
Pharmacogenomics Research Network, Pharmacogenomics Knowledge Base (PharmGKB) and 
several experts of pharmacogenomics. 
In the case of fluoropyrimidines, the CPIC guidelines consider the four DPYD variants well-known 
for the impact they have on enzymatic function and on toxicity risk: DPYD c.1905+1G>A 
(rs3918290, also known as *2A, IVS14), DPYD c.1679T>G (rs55886062, *13, p.I560S), DPYD 
c.2846A>T (rs67376798, p.D949V), and DPYD c.1129–5923C>G (rs56038477, HapB3)42. DPYD 
gene is located in the long arm of chromosome 1 (Chr1p21.3) and encodes for the initial and rate-
limiting enzyme (DPD) involved in the catabolism of the pyrimidine bases: uracil and thymine.44–46 
DPYD contains 23 exons that encode for 1,025 amino acids.47 DPD dimer activity has shown to be 




Figure 3: DPYD gene and risk variants location. Adapted from Goodsaid F. M. et al., 2010 
 
DPYD rs3918290 and rs55886062 have the most deleterious impact on DPD protein activity while 
rs67376798 and rs56038477 have a moderate impact in reducing protein activity. 
DPYD rs3918290is an intronic splicing variant which leads to the skipping of the whole exon 14, 
whereas DPYD rs55886062 and rs67376798 are two missense mutation located in exon 13 and 11, 
respectively (Figure 3). 
Rs56038477 is composed by 3 different variants in linkage disequilibrium and introduces a cryptic 
splice site in intron 10 which results in a partial production of a nonfunctional transcript (Figure 4). 





Figure 4: DPYD Haplotype B3, Van Kuilenburg, A. B. et al. 2010 
 
Rs56038477 is the most common DPYD functional variant in Europe with an allele frequency of 
4.7%. On the other hand, DPYD rs3918290, rs55886062 and rs67376798 variants are considered 
rare and common (0.2-1.6%, respectively) in Caucasian population.37 Taken together, about ~7% of 
Europeans carries at least one DPYD decreased function variant. 
To simplify and standardize the effect of these variants, DPYD alleles were scored a “gene activity 
score” (GAS), as firstly described by Steimer et al. for CPY2D6 gene allele.49,50 
DPYD alleles are divided in three categories according to the protein activity: normal metabolizer 
(value of 2), intermediate metabolizer (value of 1.0 or 1.5) and poor metabolizer (value of 0). Based 
on genotype, gene activity score represents the enzymatic phenotype of the patient. These results 
represent an easy method to describe the phenotype and can be used for adjusting the dose of FL. 
CPIC guidelines provide recommendations of different strength about better FL starting dose to use 
for each patient based on a standard method that grades levels of evidence linking DPYD alleles to 
these phenotypic categories in the literature. 
For poor metabolizers patients (GAS = 0.5 or 0), it is strongly recommended to avoid the use of 5-
fluorouracil-based regimens. If it is not possible to remove FL, a starting dose with a 75% of 
reduction is recommended (Table 1). Patients who are intermediate metabolizer (GAS = 1.0 or 1.5) 
should receive a reduced starting dose of 50% compared to the standard dose (Table 1). 
This method can be used to standardize FL dose adjustments for each patient resulting in optimal 
safety and effectiveness of FL-based regimens. Moreover, it provides the possibility to include 
novel SNPs and rare variants which may be identified by future whole exome (WES) and whole 
genome sequencing (WGS) project.49 





Table  1: CPIC recommendations 
 
Current pre-treatment DPYD genetic test including the 4 risk variants allows the prediction of the 
major number of adverse events although several toxic reactions cannot be predicted due to the low 
sensitivity of the test.51 It is important to note that patients carrying one of the four variants have a 
double risk to develop severe toxicity.51 
Although available CPIC guidelines, the application of pretreatment DPYD genotyping for clinical 
purposes is not mandatory.52,53 One reason may be the lack of information about the usefulness and 
cost‐effectiveness of pre-treatment genotyping test.53 Another limiting factor is that toxicity events 
do not always occur in the intermediate and poor metabolizer. Moreover, only the 50% of patients 
carrying at least one risk variants develop severe toxicity when treated with the standard doses. This 
issue may depend on the regimens of treatment administered or on the number of treatment’s 
cycles.54,55 On the other hand, severe toxicity may occur in wild-type DPYD patients due to 
environmental, physiological, pathological and genetics factors. Indeed, recently common 
polymorphisms in DPYD-regulatory genes and genes involved FL-detoxification pathway have 





GENOTYPES IMPLICATIONS DOSING RECOMMENDATIONS
CLASSIFICATION OF 
RECOMMENDATIONS
DPYD  Normal 
Metabolizer
2
An individual carrying two 
normal alleles
Normal DPD activity 
and “normal” risk for 
fluoropyrimidine 
toxicity
Based on genotype, there is no 
indication to change dose or 
therapy. Use label-
recommended dosage and 
administration
Strong
DPYD  Poor 
Metabolizer
0 or 0.5
An individual carrying two 
no function alleles or an 
individual carrying one no 




increased risk for 
severe or even fatal 
drug toxicity when 
treated with 
fluoropyrimidine drugs
Activity score 0.5: Avoid use of 
5- fluorouracil or 5-fluorouracil 
prodrug-based regimens. In the 
event, based on clinical advice, 
alternative agents are not 
considered a suitable 
therapeutic option, 5-
fluorouracil should be 
administered at a strongly 
reduced Activity score 0: Avoid 
use of 5-fluorouracil or 5-
fluorouracil prodrug-based 
regimens.dosek with early 
therapeutic drug monitoring
Strong
Reduce starting dose by 50% 
followed by titration of dose 
based on toxicity or therapeutic 
drug monitoring (if available). 
Patients with the 
c.[2846A>T];[2846A>T] 
genotype may require >50% 
reduction in starting dose
Activity score 1: Strong 





An individual carrying one 
normal function allele plus 
one no function allele or 
one decreased function 
allele, or an individual 




DPD activity at 30% to 
70% that of the normal 
population) and 
increased risk for 
severe or even fatal 
drug toxicity when 
treated with 
fluoropyrimidine drugs




1.4. Pharmacoeconomy  
 
The limited diffusion of preemptive DPYD tests in routine clinical practice is not only a 
consequence of the low-test sensitivity, which allow the prediction of a few number of adverse 
events (AEs), but is also caused by a limited interest from clinicians. Furthermore, the tricky 
translation of genetic information from laboratory tests to a possible therapy remains one of the 
hardest tasks for clinicians and limits these test use. Another reason may be the lack of information 
about the useful and cost‐effectiveness of pretreatment test. For these reasons, an economic 
evaluation of toxicity management costs can be a good tool to point out the utility of preclinical 
tests. 
Our earlier studies in Italian Healthcare setting indicates that patients without any DPYD risk 
variants had more quality adjusted life years (QALYs) and better clinical outcome, when compared 
with patients carrying at least one DPYD risk variants.37,56 Moreover, patients carrying DPYD risk 
variant experience higher grade toxicity events and higher management cost. Our results 
demonstrated that toxicity management cost depends on patients genotype and hospitalization is the 
most expensive intervention.57 Other studies reported similar results which remark the utility of 
DPYD pre-treatment genotyping strategies to improve patients’ therapy, quality of life and to reduce 
FL-treatment related cost.58,59 These results support the role of pharmacogenomics DPYD test as a 
powerful and cost-effective tool to improve FL-based treatment.  
 
1.5. DPYD, MTHFR and TYMS 
 
More than 160 SNPs have been reported in DPYD gene but only four of them presented a sufficient 
evidence for clinical impact to be included in the current guidelines.60 
Defects affecting other regulatory mechanisms in the expression of DPD have been extensively 
investigated and are deemed to be responsible for FL toxicity events. Indeed, DPYD locus can be 
regulated at several different levels.  
At transcriptional level, DPYD gene can be regulates by transcriptional factors AP-3 and SP-1 
binding and by additional tissue-specific transcriptional factors. DPYD promoter lacks the typical 
TATA or CCAAT boxes but have several GC-rich regions containing potential cis-regulatory 
elements.61 On these basis genetic variants in DPYD promoter region and in the transcriptional 
factors can affect the protein expression.  
At post-transcriptional level, DPD mRNA can interact with miRNA-27a and miRNA-27b. These 
two miRNAs repress DPD expression through the interaction with two conserved recognition sites 




in the 3’UTR.62 A common polymorphism (rs895819) in miRNA-27a gene (MIR27A) is associated 
with a decreased expression of DPD and with an early onset of toxicity.63  
Eventually, the methylation status of DPYD promoter seems to correlate with DPD expression in a 
tissue specific manner. It has been shown that its expression is linked to methylation status of lysine 
27 in histone H3 (H3K27) which is in turn regulated by demethylase UTX (KDM6A) and 
methyltransferase EZH2.64–67 
Several genes, in addition to DPYD, have emerged from different studies to be related to the FL-
toxicity. Among these genes the most debated are MTHFR and TYMS. 
MTHFR is a gene located in the chromosome 1 (Chr1p36.22) (Figure 5), which encodes for 
methylenetetrahydrofolate reductase (MTHFR). MTHFR protein catalyzes, as homodimer, the 
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for 
homocysteine re-methylation to methionine.68 
 
 
Figure 5: MTHFR gene. 
MTHFR known variants are associate with several diseases and clinical response to FL treatment. 
The two most common SNPs in MTHFR (rs1801133 and rs1801131) have been largely investigated 
in tumor and healthy tissues to assess if they may interfere with FL-treatment. Despite the efforts, 
no clear-cut conclusions for the association with these two polymorphism and FL-related toxicity 
emerged.69–72 
Another gene that might play a limited role in FL-related toxicity is TYMS which is located in 
chromosome 18 (Chr18p11.32) and encodes for thymidylate synthase (TS), enzyme responsible for 
the maintaining of intracellular dTMPs pool, a crucial factor for DNA replication and repair.73 
TS homodimer is the primary target of FL and in tumor tissue the different mRNA/protein 
expression of TS may influence FL-based treatments. Indeed, preclinical and in vitro studies have 
demonstrated that TS overexpression leads the development of FL resistance resulting in a poor 
response to treatment and in a lower frequency of toxicity events.74–76 On the contrary, low level of 
TS correlate with an increase sensitivity toward FL, resulting in an increased risk to developing 
toxicity and in a better response to treatment.76  
TS protein act as RNA-binding protein that negatively regulate its own mRNA by binding a stem-
loop structure in 5’UTR.77–79 Moreover, TS expression is regulated by the presence of 28bp short 
tandem enhancer repeats (TSER) at the end of 5’UTR.80  




In world population the 28bp sequence is frequently present in double (2R) or triple (3R) 
repetition.81 In vitro studies with reporter gene highlights that 3R/3R genotype have an activity of 
2.6 fold higher than that with 2R/2R genotype.77 The 3R genotype leads to an overexpression of TS 
mRNA/protein and this protects cells of both normal and tumor tissue against damages induced by 
FL therapy due to the low efficiency of TS inhibition.82,83 Patients carrying 3R/3R genotype show a 
significant lower risk of toxicity and a lower response rate when compared with 2R/2R genotype.84 
However, the role of this region is still misunderstood. A few studies have shown that at least one 
copy of the 28-bp repeat is require for stem-loop formation and transcription.85,86 Moreover, this 
mechanism might need an inverted repeat located upstream from the TSER to enhance 
expression.73,87 
Eventually, another mechanism elucidated by Dolnick et al. may influence TS expression and the 
FL-treatment outcome.88 The TYMS antisense RNA gene, ENOSF1 encodes for a mitochondrial 
protein that can generate different isoform through the alternative splicing mechanism. One of these 
has an overlapped 3’UTR with TYMS 3’UTR which allows it to bind and inactivate TS mRNA 








Figure 6: Post-trascriptional regulation of TYMS mRNA. 




1.6. Rare Variants 
 
In the last 20 years we have been witnessed to the rapid development of DNA sequencing 
techniques. From the publication of first human genome draft in 2001 to date sequencing 
technologies have undergone a remarkable evolution in both technique and costs.91–93 The constant 
decreasing of genome sequencing costs and time with a consequent increase in the number of 
sequencing projects has brought to light a large amount of gene variants and has revolutionized the 
identification of genetic disorders. 
It is widely accepted that genetic variations impact on human diseases. However, the increase 
number of projects and data provided by these platforms has shown how the presence of rare (minor 
allele frequency (MAF) ≤1) or novel variants greatly contributes to development of human diseases 
and therefore are a typical characteristic of the patient. In fact, in several databases more than 85% 
of present variants have been reported as rare.39,94–96 
Genome-wide association studies (GWAS), whole-genome and whole-exome sequencing (WGS 
and WES, respectively) revealed that rare gene variants exert larger effect than common SNPs and 
may account for a part of heritability of some human phenotype.95–97 
The advent of next generation sequencing (NGS) and the mapping of the human genome 
transformed the field of pharmacogenetics into pharmacogenomics which genetic variants, rare or 
common, in association with environmental and life style factors can affect drug adsorption, 
detoxification, metabolism, elimination (ADME) and toxicity risk.98   
Several studies reported that more than 90% of the variants in the genes associated with 
pharmacodynamics (PDs) and pharmacokinetics (PKs) phenotype is characterized by a high 
frequency of rare variants.39,98 It has been estimated that rare variants represent the 30-40% of 
functional variability in pharmacogenes, emphasizing the importance of including these variants in 
pre-treatment genetic screening in order to understand how genetic variations can be clinically 
relevant.99  
The impact of rare variants on human disease and pharmacogenomics it is also indirectly confirmed 
by the traditional approaches that consider only the common variants (SNPs) as biomarker which 
fail to fully explain the high interindividual heterogeneity.100 The rise of the NGS has allowed to 
find novel biomarkers for each patients leading to the development of precision medicine.101 
Precision medicine is aimed at identifying genetic variants, which are specific for each patient, in 
order to select the best pharmacological approach to achieve the therapeutic success, considering 
not only the efficacy of drugs administered but also their safety profile. 




Despite the inclusion of new genetic biomarkers in pre-treatment genetic test by means of high 
throughput technologies, which may play a pivotal role in the management of therapy, only a few 
rare variants are reported in the CPIC guidelines to date (e.g. DPYD*2A). 
Among the hurdles in clinical implementations of genetic tests, there is the fact that new discovered 
genetic variants with unknown functional significance require experimental control before their 
translational in clinical setting. Notably, due to the huge number of rare variants, their functional 
confirmation is not feasible.102 Moreover, association studies aimed at detecting rare variants with 
clinical impact require high statistical power with consequences prohibitively large sample sizes to 
be translated into clinical practice.99,102 
 
 






In the era of precision medicine, clinicians struggle to select the right drug at the right moment, with 
the right dosage for the right patient. Precision medicine finds a valuable ally in pharmacogenomics 
which is aimed at identifying genetic variants involved in therapeutic response and that could be 
exploited as prognostic and predictive marker of drug efficacy and toxicity. This strategy is crucial 
especially in assessing the therapeutic treatment efficacy.  
In tailored treatments, a specific attention is required for those drugs showing a low therapeutic 
index, such as chemotherapeutic agents. Among these drugs, a canonical example is provided by 
fluoropyrimidines, structural analogous of pyrimidines, composed by 5-fluorouracil (5-FU) and its 
two prodrugs capecitabine and tegafur. Fluoropyrimidines represent the backbone in the 
management of many types of solid tumours and are used in several combination regimens. 
Despite fluoropyrimidines are used for the treatment of different malignancies as colorectal, 
gastrointestinal, breast and head-neck cancers, they display a huge heterogeneity in term of efficacy 
and toxicity. Indeed, they frequently lead to severe toxicity resulting in treatment interruption and 
delay in therapy administration. Unfortunately, these outcomes lead not only to treatment failure but 
also to discomfort for patients. Moreover, the Adverse Drug Reactions (ADRs) lead to a sharp rise 
in the cost for toxicities management for the National Healthcare Systems (NHSs), as reported by 
our group.   
Fluoropyrimidines display a low therapeutic index which results in a narrow range of plasma 
concentration between the minimum effective dose (MED) and the maximum tolerated dose 
(MTD). Given this characteristic, it is reported that about 26% of patients experience severe drug-
related hematologic toxicity, non-hematologic toxicity or a combination of them in course of FL-
based treatment. Ultimately, FL-related toxicities lead to death in about 0.1% of cases. This 
phenomenon can be caused by a low clearance of the drug, thus leading patients to be exposed to 
drug concentration in plasma above the therapeutic window.   
The 85% of 5-FU is metabolized in the liver by dihydropyrimidine dehydrogenase (DPD) enzyme 
into the inactive metabolite dihydrofluorouracil (DHFU), excreted in urine by kidneys catabolism. 
The Clinical Pharmacogenetics Implementation Consortium (CPIC) suggests a genetic test for the 
assessment of DPD catabolic activity before fluoropyrimidine-based treatment. 
The currently validated genetic screening is based on four genetic variants associated to a reduced 
activity of DPD enzyme that are known to be related to fluoropyrimidines toxicity. DPD enzyme is 
encoded by DPYD gene, located in p21.3, the small arm near the centromeric region of 




human chromosome 1. DPYD*2A (c.1905+1G>C or rs3918290) and DPYD*13 (c.1679T>G or 
rs55886062) are the most deleterious variants described in DPYD gene, whereas DPYD c.2846A>T 
(rs67376798) is associated to a less deleterious phenotype. Recently, a novel haplotype (Hap-B3) of 
DPYD gene has been identified and associated to an altered functionality of the enzyme resulting in 
a higher risk to develop severe toxicity (G≥3). PGx guidelines are not mandatory in clinical practice 
yet and the genetic test is still scarcely widespread among clinicians. Moreover, the low frequency 
of DPYD variants in the population negatively affect the adoption of pre-treatment genotyping. 
The four SNPs-based genotyping tests showed a high specificity in predicting FL-related toxicities 
but a low sensibility. Consequently, these analyses do not allow the prediction of all toxicity events 
related to fluoropyrimidines treatment. Several recent studies suggest that novel and rare germline 
variants in pharmacogenes might contribute to the reported interindividual variability. 
 






In this PhD thesis, we aimed at improving the knowledge on the clinical validity and clinical utility 
of the DPYD clinical diagnostic test proposed by the current pharmacogenomic guidelines, by 
investigating the impact of the four DPYD variants on fluoropyrimidines-related toxicity and cost. 
In addition, we analysed the contribution of novel and rare genetic variants in the development of 
fluoropyrimidines-related toxicity.  
The project was designed and structured to analyse in depth the impact of patient genotype in the 
exacerbation of FL-related toxic effects. Therefore, we can summarize our work in three main parts: 
• In the first part, we aimed at validating the clinical value of the pre-emptive DPYD test on a 
retrospective population of patients with CRC treated with FL-based regimens. We selected 
763 patients with CRC for whom detailed toxicity events reported during FL-based 
chemotherapy were recorded. We genotyped them for the four DPYD risk variants 
(rs3918290, rs55886062, rs67376798 and rs56038477) by means of different sequencing 
technologies (Pyrosequencing, Real-Time PCR and Sanger Sequencing). Functional impact 
of these variants has been assessed by using a “gene activity score” (GAS), according to 
CPIC guidelines. 
• In the second part, we hypothesized that the DPYD risk genotype could be not only 
associated to an increased risk of developing severe toxic events, but also to an increased 
cost for National Health Care System due to their clinical management. We analysed for the 
first time a subpopulation of 550 patients affected by CRC and assessed a relationship 
between DPYD genetic variants, toxicity and cost derived from the management of them.  
• In the third part, we aimed at investigating the role of rare and novel germline variants in a 
panel of candidate genes involved in the FL-pathway to assess the relationship between rare 
variants and severe toxicity onset. To achieve this goal, we sequenced, by means of NGS in 
Illumina platform (MiSeq), a selected subpopulation of 108 DPYD wild type patients who 
experienced an extreme toxicity phenotype (grade 3 to 5) after or during FL-based 
treatment. As control group, we sequenced a cohort of 106 DPYD wild type patients treated 
with a fluoropyrimidine-based regimens who did not experienced severe toxicities (grade 0 
to 2).  






4.1 Association between DPYD genotype and FL-related DLTs 
 
A final set of 763 patients with CRC treated with FL-based chemotherapy was selected to assess the 
relationship between the 4 DPYD risk variants in clinical genetic test and the risk to develop 
adverse reactions and eventually stratifying patients according to the DPYD genetic activity score 
(GAS) model. Patients detail concerning genotyping results, age, gender, chemotherapy regimens 
and radiotherapy exposure are listed in Table 2.  
Characteristic N % 
Sex    
Male  479 62.8 
Female 284 37.2 
Age (years)    
Median (range)  61 (20–85)   
FL- association therapy 
Monotherapy 229 30 
Oxaliplatin 265 34.7 
Irinotecan 269 35.3 
Radiotherapy    
Yes  197 25.8 
No  566 74.2 
DPYD genotype 
rs3918290 9 1.2 
rs55886062 0 0.0 
rs67376798 5 0.7 
rs56038477 31 4.1 
Table  2: Cohort of 763 patients and their characteristics 
Concerning the primary tumor site, in this cohort 423/763 (55.4%) patients had colon cancer while 
340/763 (44.6%) patients had rectal cancer. As far as the treatment is concerned, 196/763 (25.7%) 
patients were treated in neo-adjuvant setting, 282/763 (37%) were treated in adjuvant setting, 
279/763 (36.6%) were treated with the first-line treatment for metastatic disease while the 
remaining 6/763 (0.8%) were treated with the second-line. 
All 763 patients were successfully genotype for the 4 DPYD risk variants. All polymorphisms were 
detected in heterozygosity and not compound heterozygosity was detected. Only 45 (5.9%) patients 
carried at least one DPYD variants, while the remaining 718 (94.1%) resulted wild type. 
Specifically, 9 (1.2%) patients carried the DPYD rs3918290 variant, 5 (0.7%) and 31 (4%) patients 




carried rs67376798 and rs56038477 DPYD variants, respectively. No patients carrying DPYD 
rs55886062 allele were detected. 
Patients were then classified according to the GAS model. 9 (1.2%) patients were associated to 
DPYD activity score of 1.0, as all of them harbored rs3918290 variant, while the remaining 36 
(4.71%) DPYD mutated patients were associated to a 1.5 score. The 718 (94.1%) wild-type patients 
were considered as full-metabolizer (GAS = 2.0). 
In the whole population, 178 (23.3%) patients developed at least one toxicity during the entire 
course of chemotherapy that was classified as a dose-limiting toxicitie (DLT), whereas 583 (76.7%) 
did not. Among patients who experienced DLT, 38/178 (21.3%) developed grade 4 hematological 
toxicity as the most severe toxicity reported, 154 (86.5%) developed grade 3 or 4 non-hematological 
toxicity and 14 (7.9%) experienced both of them. Looking at the acute toxicities, 108 (14.2%) 
patients develop DLTs within the first three cycles of treatment, and 655 (85.8%) patients did not. 
Among patients who developed DLTs, 22/108 (20.4%) developed hematological toxicities, 94 
(87%) non-hematological and 8 (7.4%) both (Table 3). Of the 178 (23.3%) patients experiencing 
DLTs during the entire course of chemotherapy, the most common adverse events were hand-foot 
syndrome, neurological disorders, neutropenia, leukopenia and gastrointestinal toxicities, mainly 
represented by diarrhea and vomiting. 
  Acute  Total 
DLT  N  %   N  % 
All      
No  655 85.8  858 76.7 
Yes  108 14,2  178 23,3 
Haematological     
No  741 97.1  725 95.0 
Yes  22 2.9  38 5.0 
Non-haematological    
No  669 87.7  609 79.8 
Yes  94 12.3   154 20.2 
Table  3: Distribution of acute and total dose limiting toxicity (DLT) 
As expected, the onset of DLT is significant associated (P=0.0009) with the presence of at least one 
DPYD variant within the 4-SNP panel analyzed. Indeed, carriers of at least one variant had about a 
2.7-fold increased risk to develop at least one DLT when considering both acute and total toxicity 
(Table 4). Specifically, patients carrying at least one DPYD variant who developed a DLT within 
the first three cycles (acute toxicity) and within entire course of treatment (overall toxicity) account 
for the 28.9% and 44.4%, respectively. On the contrary, only the 13.2% and the 22% wild-type 
DPYD patients experienced DLTs during the first three cycles and during the whole course of 
treatment, respectively.  




However, it was shown that the GAS better defined the risk to develop DLTs than the single DPYD 
allele approach. Indeed, the risk (OR) to develop DLT was 2.08 (95% CI = 1.02-4.27) and 7.09 
(95% CI = 1.69-29.65) in patients with GAS = 1.5 and 1.0, respectively when compared with 
patients bearing a GAS = 2 (Table 4). 
      Acute   Total 
  N % OR 95% CI   OR 95% CI 
SNP panel 45 5.9 2.69 1.33-5.41  2.67 1.42-5.04 
DPYD activity score        
2 718 94.1 1   1  
1.5 36 4.7 1.80 0.78-4.15  2.08 1.02-4.27 
1 9 1.2 10.12 2.55-40.2  7.09 1.69-29.65 
χ2 for trend    P=0.0007   P=0.0009 
Table  4: Association of DPYD variants with dose-limiting acute and total toxicity 
 
For acute toxicity, the risk (OR) was 1.80 (95% CI = 0.78-4.15) and 10.12 (95% CI = 2.55-40.20) in 
patients with GAS = 1.5 and 1.0, respectively (Table 4). Among the patients with a GAS of 1.0, 6/9 
(66.7%) showed the onset of DLT during the whole course of treatment and, 5/9 (55.6%) developed 
DLT within the first three cycles. Among patients with a GAS of 1.0, 14/36 (38.9%) showed DLT 
during the entire course of chemotherapy and 8/36 (22.2%) reported DLT within the first three 
cycles of treatment. On the other hand, wild-type patients (GAS = 2.0) presented DLT in 158/718 
cases (22.0%) when considering the whole treatment and in 95/718 cases (13.2%) when considering 
the first three cycles of therapy. The toxicity grade developed in relation to the GAS is reported in 
Figure 7: within the first three cycles of chemotherapy (A) and during the entire treatment (B). 
Toxicities were classified as mild (grade from 0 to 2), severe (grade 3) and very severe (grade 4). 
Patients with a DPYD GAS of 1.0 were more likely to develop grade 4 toxicity rather than other 
patients while patients with a DPYD GAS of 1.5 showed an increased risk to develop grade 3 
toxicity rather than wild-type DPYD patients (Figure7). 
 
Figure 7: Toxicity grade (by NCI CTC scale) distribution according to the DPYD activity score model within the first 
three cycles of chemotherapy (A) and during the whole treatment (B). 




4.2. Toxicity and costs associated with its management 
 
To estimate the relationship between DPYD risk genotype, toxicity and costs associated with its 
clinical management, we selected, based on inclusion criteria, 550 patients affected by CRC and 
treated with a chemotherapy based on the use of fluoropyrimidines. 
Patients’ characteristics are listed in Table 5.  
    Chemotherapyr egimen 






All 550 84 265 201 
Sex     
Male 330 (60%) 54 (64.3%) 171 (64.5%) 105 (52.2%) 
Female 220 (40%) 30 (35.7%) 94 (35.5%) 96 (47.8%) 
Age (years)     
<60 208 (37.8%) 17 (20.2%) 107 (40.4%) 84 (41.8%) 
60-69 211 (38.4%) 18 (21.4%) 120 (45.3%) 73 (36.3%) 
≥70 131 (23.8%) 49 (58.3%) 38 (14.3%) 44 (21.9%) 
TNM stage at diagnosis    
I-II 83 (15.1%) 30 (35.7%) 26 (9.8%) 26 (12.4%) 
III  275 (50%) 42 (50%) 70 (26.4%) 163 (81.1%) 
IV 192 (34.9%) 12 (14.3%) 169 (63.8%) 11 (5.5%) 
Setting of treatment     
Adjuvant 270 (49.1%) 71 (84.5%) 5 (1.9%) 194 (96.5%) 
First/second line  280 (50.9%) 13 (15.5%) 260 (98.1%) 7 (3.5%) 
Number of cycles received    
1–6  196 (35.6%) 49 (58.3%) 115 (43.4%) 32 (15.9%) 
7–12  331 (60.2%) 35 (41.7%) 127 (47.9%) 169 (84.1%) 
≥13  23 (4.2) 0 (0%) 23 (8.7%) 0 (0%) 
Type of fluoropyrimidine    
5-Fluorouracil 485 (88.2%) 58 (69.1%) 265 (100%) 162 (80.6%) 
Capecitabine 65 (11.8%) 26 (30.9%) 0 (0%) 39 (19.4%) 
Table 5: Characteristics and demographics of 550 patients 
 
In this cohort 485 (88.2%) patients were treated with 5-fluorouracil, and 65 (11.8%) with 
capecitabine. Fluoropyrimidine monotherapy was used in 15.3% of patients and all patients were 
treated with a full starting dose of FL.  
DPYD genotyping was performed retrospectively after treatment conclusion.  
To investigate a possible association between DPYD genotype and treatment interruption or 
discontinuation, we systematically collected patients´ clinical record concerning both treatment 
interruption and the FL dose reduction during chemotherapy as a consequence of intolerance toward 
the drug. According to this survey, during the treatment course a FL dose reduction was reported in 
123/550 (22.4%) patients. Intriguingly, in 27 of them the treatment discontinuation was required as 




a consequence of toxicity reported. In addition, other 86/550 (15.6%) patients discontinued therapy 
prematurely without undergoing FL dose reduction. A treatment interruption occurred in 47/550 
(41.6%) patients as a consequence of chemotherapy-related toxicity, in 21 (18.6%) patients as a 
consequences of early disease progression, in 14 (12.4%) patients due to patient refusal and in 13 
(11.5%) patients due to other causes. Treatment interruption occurred in other 11 (9.7%) patients 
due to disease progression, in 4 (3.5%) patients due to death and eventually in 3 (2.7%) patients due 
to lost to follow-up. 
In the whole population, during the first 12 cycles of treatment, 4,052 toxic adverse reactions of any 
grade were reported, with a mean of 8.2 events for patient (range 0-33). The most common 
toxicities were hematological (1,581; 39%) and gastrointestinal (1,144; 28.2%), followed by 
neurological (649; 16%) and cardiovascular (18; 0.4%). However, no toxic death was reported. 
Among the adverse reactions, 1,214 (30%) events required additional costs for their management 
and 84 (2.1%) led to patient hospitalization. In this cohort, the average cost for the management of 
adverse reactions was €930 per patient (range €0-€31,454). All grade 3 and 4 toxicity reactions 
were associated with a cost for their management, whereas only 19.7% and 38% of grade 1 and 2 
were associated with a toxicity management cost, respectively. Grade ≥3 cardiovascular toxicities 
and all type of grade 4 required hospitalization, whereas the higher cost was attributed to febrile 
neutropenia (€6,102 per episode). Moreover, the cost of grade 3 thrombocytopenia or anemia was 
€653 per episode and €75 for nausea or vomiting. 
Among this cohort of 550 patients, only 37 (6.7%) patients were DPYD carriers and all of them 
were heterozygous for one of the four risk variants. In these patients carrying at least one DPYD 
variant, no homozygous or compound heterozygous patient was detected. Specifically, 9 (1.6%) 
patients were heterozygous for rs3918290, 5 (0.9%) for rs67376798, 23 (4.2%) for rs56038477 and 
finally no one carried rs55886062. 
Concerning GAS, 513 (93.3%) patients had a score of 2.0, 28 (5.1%) of 1.5, 9 (1.6%) of 1.0 and no 
patients had a score of 0. Carriers of one DPYD risk variants had a mean toxicity management cost 
of €2,972 (95% CI = €2,456-€3,505), which was significantly higher than noncarriers (€825; 95% 
CI = €785-€864; P<0.0001). The 37 (6.7%) DPYD carriers accounted for €109,964, which is 20.7% 
of the overall cost (€529,085). The mean cost per patient was inversely related to the GAS (P< 
0.0001) (Table 6). 
 
 




    Cost (€) 
DPYD variant status N Mean 95% CI ANOVA 
Noncarriers 513 825 785-864  
Carriers 37 2,972 2,456-3,505 P< 0.0001 
Gene activity score (GAS)    
2 513 825 785-864  
1,5 28 2,188 1,683-2,693  
1 9 5,414 2,268-8,561  
0 0 0 0 P< 0.0001 
Table  6: Association between DPYD variants and the toxicity management costs 
 
Carriers were significantly at increased risk of developing an adverse reaction requiring 
hospitalization than noncarriers (OR, 4.14; 94% CI = 1.87-9.14; P = 0.0004, ANOVA). A display 
of the incidences of these two types of toxic events by cycle and carrier status is reported in Figure 
8. 
 
Figure 8: Percentage of patients experiencing toxicities requiring hospitalization (a) or toxicities associated with any 
management cost (b) 
 
No significant association was found with the risk of developing toxic events associated with any 
management costs (Table 7). 
  Noncarriers   Carriers   
  N (%)   N (%) OR (95% CI) 
Patients with toxicities associated with any management cost 
No 147 (28.7)  8 (21.6) Reference 
Yes 366 (71.3)  29 (78.4) 1.52 (0.67-3.47) 
    P = 0.3172 
Patients with toxicities requiring hospitalization  
No 463 (90.3)  26 (70.3) Reference 
yes 50 (9.7)  11 (29.7) 4.14 (1.87-9.14) 
        P = 0.0004 
Table 7: Association between DPYD variants and toxicities associated with any management cost and toxicities 
requiring hospitalization 




Patients treated with FL monotherapy had a mean toxicity management cost of €352 (95% CI = 
€269-€409), while patients treated with irinotecan in combination with FL resulted in a mean 
management cost of €798 (95% CI = €709-€887) and, eventually, patients treated with 
fluoropyrimidines/oxaliplatin resulted in a mean cost of €1,459 (95% CI = €1,260-€1,659; P< 
0.0001).  
Figure 9 reports the toxicity management cost according to the chemotherapy regimen and 
treatment cycle, without taking into account the cost of the drugs. It is possible to note that the cost 
for the three regimens were very similar during the first cycles but that they tend to decrease in the 
following cycles (cycles 7-9). According to the previous results, hospitalization occurred in 31/201 
(15.4%) of patients treated with fluoropyrimidine/oxaliplatin, in 20/265 (7.4%) patients receiving 
fluoropyrimidine/irinotecan, and in 5/84 (5.9%) patients treated with fluoropyrimidines 
monotherapy (P = 0.007; χ2test). Figure 9 showed the trend which is consistent with a difference in 
hospitalization rates. 
 
Figure 9: Toxicity management cost per patient according to the treatment cycle and chemotherapy regimen 
 
The effects of the DPYD status and GAS on toxicity management costs were also evaluated in 
relation to the different chemotherapy regimens and remained significant higher for DPYD risk 
variants carriers in all three regimens (Table 8). Within each chemotherapy regimen, the cost 
related to DPYD carriers was about 3.5-fold higher than for noncarriers. Moreover, we performed a 
second economic analysis to estimate the cost of DPYD-guided toxicity management and the 
clinical benefit expressed as quality adjusted life years (QALYs)56. 
These studies suggest that the incremental costs were mainly driven by higher percentage of severe 
ADRs in poor/intermediate metabolizer than in full metabolizer patients. 
 
 




    Cost (€) 
DPYD variant status N (%) Mean (95% CI) ANOVA 
Fluoropyrimidine monotherapy   
Noncarriers 79 (94.1) 320 298-342  
Carriers 5 (6.0) 1,208 0-2,658 P< 0.0001 
Gene activity score     
2 79 (94.1) 320 298-341  
1.5 3 (3.6) 471 0-1,529  
1 2 (2.4) 2,315 0-11,353  
0 0 (0) 0 0  
Fluoropyrimidine/irinotecan    
Noncarriers 249 (94.0) 662 630-695  
Carriers 16 (6.0) 2,385 918-3,851 P< 0.0001 
Gene activity score     
2 249 (94.0) 662 630-695  
1.5 12 (4.5) 1,031 618-1,443  
1 4 (1.5) 6,447 2,241-10,654  
0 0 (0) 0 0  
Fluoropyrimidine/oxaliplatin    
Noncarriers 185 (92.0) 1,269 1,212-1,326  
Carriers 16 (8.0) 4,808 1,529-8,087 P< 0.0001 
Gene activity score     
2 185 (92.0) 1,269 1,212-1,236  
1.5 13 (6.5) 2,68 910-2,754  
1 3 (1.5) 16,183 516-31,850  
0 0 (0) 0 0   
Table 8: Association between DPYD variants and the toxicity management costs in patients undergoing different 
chemotherapy regimens 
 
4.3. Rare variants, cases cohort 
 
To assess the role of novel and rare variants in the onset of fluoropyrimidine-related toxicity, we 
sequenced a selected cohort of 120 patients through a Miseq (Illumina) platform. Of these, 12 
patients were discarded due to the low quality reads. Patients characteristics are listed in Table 9.  
Patients were selected according to specific inclusion criteria listed in Material and Methods 
(section 6.1). Briefly, only patients who experienced at least one event of severe (grade >= 3) 
toxicity were included. For them, the DPYD genotype for the four variants (rs3918290, 
rs55886062, rs67376798 and rs56038477) was previously assessed to be sure that only DPYD wild-
type patients had been included in this analysis. Thus, only patients with DPYD GAS = 2.0 were 
considered to rule out the impact of any DPYD variant on patients phenotype (toxicity) 
As reported in Table 9, the gender of the population was equally distributed, with a slight majority 
of female 59 (54.6%) over male (44.4%). Average age of enrollment was 60 years ranging between 




30-82. Considering the primary tumors site, 87 (80.6%) patients had colorectal cancer, 6 (5.6%) had 
breast tumor, 5 (4.6%) had gastric cancer, 2 (1.8%) had head-neck tumor, 1 (0.9%) patient had 
cervical tumor and 1 (0.9%) had pancreatics cancer, whereas the remaining 6 (5.6%) had not 
available information about primary tumor site.  
Concerning the therapy, fluoropyrimidine monotherapy was used in 8 (7.4%) patients while 
combination treatment was used in 100 (92.6%) patients. Among these 100 patients, 37 (34.3%) 
were treated with irinotecan, 37 (34.3%) and 7 (6.5%) patients with cisplatin and oxaliplatin 
respectively. 6 (5.5%) patients were treated with a combination of irinotecan and cisplatin and 13 
(12%) were treated with other combination regimens. Moreover, 87 (80.6%) patients were treated 
with a base of 5-FU while 21 (19.4%) were capecitabine-based treatment. 
Concerning ADR reported in this cohort, 61 (56.5%) patients developed grade 3 toxicity, 46 
(42.6%) developed G4 toxicity and 1 patient died for toxicity (grade 5). Moreover, in 98 (90.7%) 
patients the onset of severe toxicity occurred during the first 3 cycles of treatment (acute toxicity), 
while in 6 (5.6%) patients it occurred after 3 cycles (total or delayed toxicity). Unfortunately, for 4 
(3.7%) patients detailed toxicity data were not available. 
  Patients   Treatment 
Characteristic N° (%)   5-FU N° (%) Capecitabine N° (%) 
All 108  87 (80.6%) 21 (19.4%) 
Age     
Mean (range) 60 (30-82)  60 (30-82) 60 (39-79) 
Sex     
Male 49 (44.4%)  40 (45.9%) 9 (42.9%) 
Female 59 (54.6%)  47 (54.1%) 12 (57.1%) 
Type of cancer     
ColoRectal 87 (80.6%)  75 (86.2%) 12 (57.1%) 
Breast 6 (5.6%)  4 (4.6%) 2 (9.5%) 
Gastric 5 (4.6%)  2 (2.3%) 3 (14.3%) 
Head-Neck 2 (1.8%)  2 (2.3%) / 
Cervical 1 (0.9%)  1 (1.2%) / 
Pancreas 1 (0.9%)  / 1 (4.8%) 
N.A. 6 (5.6%)  3 (3.4%) 3 (14.3%) 
Treatment      
Monotherapy 8 (7.4%)  2 (2.3%) 6 (28.6%) 
Combination: 100 (92.6%)  85 (97.7%) 15 (71.4%) 
Platin 37 (34.3%)  36 (41.4%) 1 (4.8%) 
Irinotecan 37 (34.3%)  37 (42.5%) / 
Oxaliplatin 7 (6.5%)  / 7 (33.3%) 
Platin + Irinotecan 6 (5.5%)  4 (4.6%) 2 (9.5%) 
Others 13 (12%)   8 (9.2%) 5 (23.8%) 
                                                                                                                    (Continued on the next page) 
 




Continued Patients  Treatment 
Characteristic N° (%)   5-FU N° (%) Capecitabine N° (%) 
Max Grade Toxicity (all)     
G5 1 (0.9%)  1 (1.1%) / 
G4 46 (42.6%)  36 (41.4%) 10 (47.6%) 
G3 61 (56.5%)  50 (57.5%) 11 (52.4%) 
Severe Toxicity (≥G3)     
Acute (During the firsts 3 cycles) 98 (90.7%)  79 (90.8%) 19 (90.5%) 
Delayed or Total (After cycle 3) 6 (5.6%)  6 (6.9%) / 
N.A. 4 (3.7%)   2 (2.3%) 2 (9.5%) 
Table 9: Cases cohort characteristics  
 
4.4. Rare variants distribution in the cases cohort 
 
Sequencing data of the 108 patients from the cases cohort revealed a total of 19,960 variants 
distributed in 54 candidate genes. Notably, 961 unique variants were detected, which included 
common polymorphisms, rare and novel variants. In agreement with the fact that the untranslated 
regions (UTRs) are not high conserved, most variants fall on UTRs (602; 62.64%). Among these, 
526 (54.73%) fall on 3’UTRs and 76 (7.91%) fall on 5’UTRs. Exonic variants were divided into 
missense (168; 17.48%), synonymous (166; 17.27%), stop gain (5; 0.52%), frameshift (4; 0.41%) 
and others (10; 1.04%) that include in-frame insertion and deletion (Figure 9). Then, 6 (0.62%) 
variants were deemed to influence the splicing sites.  
 
Figure 9: Variants types distribution across 54 target gene in cases cohorts 
To understand if any gene could be enriched in a specific type of variant, we have plotted the class 
of variants identified on each gene (Figure 10a, b).  




Except for a few genes, most genes are enriched for variants in the UTR, as expected. By contrast, 
the DPYD gene, which encodes for the main metabolizer of the drug, is enriched in missense 
variants (Figure 10a, b). 
 
Figure 10a: Variants distribution per gene  
 
Figure 10b: Variants distribution per gene 
However, the number of variants per gene may depend on the length of coding sequence (CDS), on 
the length of UTRs and on other characteristic of gene and DNA sequence. To assess whether the 
distribution of variants is influenced by the length of the gene, we normalized the number of 
variants for the length of each gene. With this in mind, we reported in dark blue the total number of 
variants normalized for the gene length and in red the number of exonic variants normalized for the 
exon length, respectively (Figure 11a, b). After normalization, it appears evident that some genes 





































































































































































































































































per kbs detected. Moreover, the length of UTRs or genes does not seem to influence the number of 
variants per genes in all genes. 
 
Figure 11a: Variants distribution per gene normalized on the gene length  
 
Figure 11b: Variants distribution per gene normalized on the gene length 
 
According to the idea that a rare variant is supposed to have a stronger impact on phenotype we 
investigated the distribution of variants based on their minor allele frequency (MAF). Among these 
unique 961 variants, 434 (45.2%) are rare with a MAF<0.01, 273 (28.4%) are very rare variant 






























































































































































































































































Figure 12: Variants distribution according to Minor Allele Frequency (MAF) 
In addition, we speculated that the number of variants in a single gene may reflect a difference in 
the role in the onset of toxicity events. To verify our hypothesis, we clustered the genes into 4 main 
classes, such as DPYD, transporters, genes belonging to folate pathway, nuclear receptors and 
others. 
Bearing in mind that a rare variant has a high probability of being dangerous for the normal 
function of protein, and we observed that DPYD and genes involved in folate pathway show an high 
number of novel, very rare and rare variants, perhaps suggesting a functional role of these variants 
(Figure 13).  
 
































4.5. DPYD rare, very rare and novel variants 
 
In the cases cohort, we highlighted 9 different very rare variants (MAF <0.001) on DPYD. For 
them, no compound heterozygous or homozygous patients were found. Table 10 shows the DPYD 
rare variants. All variants were confirmed by Sanger sequencing. 
DPYD: NM_000110 





P1 c.G345C; p.M115I rs377169736 Exon5 Missense 0.0001 
P2 c.G481A; p.E161K / Exon5 Missense / Splice / 
P3 c.C800T; p.T267I / Exon 8 Missense / Splice / 
P4 c.G958A; p.G320R / Exon9 Missense / Splice / 
P5 c.A1110G; p.I370M / Exon 10 Missense / Splice / 
P6 c.A1411C; p.T471P / Exon12 Missense / Splice / 
P7 c.A2060C; p.D687A rs755692084 Exon 17 Missense / Splice 0.00002* 
P8 c.A2137G; p.N713D rs773407491 Exon 17 Missense / Splice 0.000008247 
P9 c.T2491A; p.C831S / Exon 20 Missense / Splice / 
Table 10: DPYD rare variants (MAF <0.01) 
In the P1 proband, a 60 year-old female, we highlighted a very rare missense variant (c.345C>G; 
p.M115I; rs377169736) which falls on exon 5 of DPYD (Figure 14a).  
          
Figure 14: Electropherogram related to DPYD variants in patient P1(a) and in patient P2 (b) 
The missense variant was reported as a very rare variant from both the databases dbSNP and ExAc. 
Interestingly, in this patient a common variant (c.T2C; p.M1T; rs2228570) on vitamin D receptor 
(VDR) that may lead to severe defect in the normal mRNA translation chemistry was present. P1 
was affected by colorectal cancer and was treated in adjuvant setting with a combination of 
capecitabine and oxaliplatin (CAPOX). The patient developed a severe gastrointestinal toxicity 
(diarrhea G4) after the first cycle of treatment which led to a reduction in the dosage of the FL drug. 
The proband P2 was a 42 year-old female treated with cyclophosphamide, methotrexate, and 
fluorouracil (CMF) combination for the treatment of breast cancer. After only one cycle of therapy 
she experienced a hematological toxicity (leukopenia G4) that led to FL dose reduction. P2 
presented a novel missense variant on DPYD (c.481G>A; p.E161K) (Figure 14b). Moreover, in this 
a)                                                              b) 
Exon 5                      Intron 5 




patient a very rare synonymous (c.4185A>G; p.P1395P; rs778920577) variants on DPYD’s 
regulator lysine (K)-specific demethylase 6A (KDM6A) was found. 
P3 proband was a 47 year-old female affected by CRC and treated with a FOLOFOX-4 regimen 
that includes 5-FU and oxaliplatin. P3 developed acute non hematological G3 toxicity after the first 
cycle of therapy. NGS sequencing revealed the presence in heterozygosis of a novel variant into 
exon 8 (c.800C>T; p.T267I) of DPYD gene (Figure 15a). 
              
Figure 15: Electropherogram related to DPYD variants in patient P3(a) and in patient P4 (b) 
Another novel missense (c.958G>A; p.G320R) variant which fall on exon 9 was found in proband 
P4 (Figure 15b). This patient was a 64 year-old male with a CRC treated with FOLFOX-4 regimen. 
He developed a severe G4 neutropenia which led to dose reduction after the second cycle of 
therapy. 
Proband P5, a 54 year-old male, experienced not hematological G4 toxicity after one cycle of 
FOLFOXIRI (fluorouracil, oxaliplatinum, irinotecan) regimen plus monoclonal antibody 
Cetuximab. P5 was characterized by the presence of a novel missense variant (c.1110A>G; 
p.I370M) in exon 10 of DPYD (Figure 16a). Interestingly, this patients showed the presence of 
other variants in DPYD’s regulatory genes: one very rare (c.380G>A; p.R127Q; rs371659081) 
variant on nuclear receptor subfamily 1, group I, member 2 (NR1I2) and one rare missense 
(c.803C>T; p.A268V; rs1042311) variants in peroxisome proliferator-activated receptor alpha 
(PPARA). Furthermore, this patient carried a common polymorphism (n.40A>T; rs895819) on 
MIR27A which is a direct regulator of DPD expression. This polymorphism is already known to 
lead to an increased risk of developing FL-related toxicity in patients carrying at least one DPYD 
risk variant 103. 
           
Figure 16: Electropherogram related to DPYD variants in patient P5(a) and in patient P6 (b) 
Exon 9                   Intron 9 
a)                                                                  b) 
a)                                                              b) 




P6 proband, was a male 64 year-old patient affected by CRC treated with FOLFIRI regimen who 
developed a G3 neutropenia after the first cycle of therapy. After target sequencing a novel 
missense (c.1411A>C; p.T471P) variant on exon 12 of DPYD has emerged (Figure 16b). As P5, P6 
carried a MIR27A risk variant (n.40A>T; rs895819) in addition to a rare missense (c.1582G>A; 
p.A528T; rs45605536) variant on ATP-binding cassette, sub-family G (WHITE), member 2 
(ABCG2), a transporter that regulates the intracellular efflux of 5-FU. 
In the P7 proband, 57 year-old female, we found in exon 17 of DPYD a very rare missense 
(c.2060A>C; p.D687A; rs755692084) (Figure 17a). Moreover, we identified the MIR27A risk 
variant (n.40A>T; rs895819). The proband developed acute toxicity after three cycle of therapy 
with FOLFIRI regimen, which include a combination of 5-FU and irinotecan. Specifically, she 
developed neutropenia G3 and stomatitis G3.  
             
Figure 17: Electropherogram related to DPYD variants in patient P7(a) and in patient P8 (b) 
Proband P8 carried a very rare missense variants (c.2137A>G; p.N713D; rs773407491) on exon 17 
of DPYD (Figure 17b). Furthermore, P8 proband showed the presence of one rare missense 
(c.92G>A; p.G31D; rs137853247) variants in Hepatocyte Nuclear Factor 1-Alpha (HNF1A) and 
one (c.1126A>C; p.T376P; rs771937539) on Hepatocyte Nuclear Factor 1-Beta (HNF1B), two 
transcriptional factors express in liver involved in the DPYD’s expression. P8 was a 77 year-old 
male affected by CRC who developed non hematological G4 toxicity after the first cycles of 
capecitabine treatment. 
P9 proband is a male patient treated with capecitabine for metastatic disease that developed a severe 
(G4) hematological and non-hematological toxicity. However, for this patient, information about 
age, first tumor site and cycle of toxicity were not available. From NGS a novel missense 
(c.2491T>A; p.C831S) variant that falls in exon 20 has emerged (Figure 18). Furthermore, NGS 
highlighted the MIR27A risk variant (n.40A>T; rs895819). Among the others, we found very 
interesting the novel 43bp long deletion (c.*941_*983del) variant found on overlapped 3’UTR of 
the TYMS and its antisense overlapping gene ENOSF1. 
a)                                                               b) 
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Figure 18: Electropherogramrelated to DPYD variants in patient P9 
4.6. Rare, very rare and novel variants in FL-pathway 
 
NGS allowed us to highlight 9 rare (MAF <0.01) variants on DPYD in a cohort of 108 patients. 
However, 99 patients did not present any variant on the candidate genes and, even assuming that all 
the previously nine variants would be pathological, we cannot define a straightforward explanation 
for all the episodes of severe toxicity. Nevertheless, we found out other five rare variants that may 
explain the onset of toxicity in other six patients. 
The proband P10 was a male 73 year-old affected by CRC and was treated with FOLFOX regimen 
that led to an acute neutropenia G3 at the third cycle. In P10 we highlighted a novel frameshift 
deletion (c.1774delT; p.C592fs) on ABCG2 gene. 
Patient P11, a 52 year-old male with CRC, was treated with FOLFIRI regimen. He developed a 
severe G4 neutropenia at the second cycle of treatment. Sequencing data shows the presence of a 
rare variant, a stop gain (c.297G>A; p.W99X; rs145048685) mutation, on ATP-binding cassette, 
sub-family C (CFTR/MRP), member 11 (ABCC11). 
Proband P12 carried a very rare stop gain (c.G2490A; p.W830X; rs767682650) mutation on 
ABCC11 and the common MIR27A risk variant (n.40A>T; rs895819). P12 was a 68 year old female 
affected by CRC, she developed a non-hematological G3 toxicity during the first cycle of FOLFOX 
treatment. 
P13 shows a novel frameshift insertion (c.1213_1214insC; p.K405fs) on enhancerof zeste homolog 
2(Drosophila) (EZH2). P13, a 66 years-old female affected by CRC, experienced a G3 neutropenia 
after one cycle of FOLFIRI therapy. 
Finally, a novel synonymous variant (c.783C>G; p.G261G) on MTHFR genes which seem affected 
the splicing was found un two unrelated patients (P14 and P15). These patients were treated with 
FOLFIRI regimen for CRC and both developed a non-hematological G3 toxicity. P14 and P15 were 








4.7. Prediction tools analysis 
To predict the impact of novel and rare variants on DPD seven prediction tools were leveraged: 
SIFT104, Polyphen-2105, PROVEAN106, CADD107, LRT108, MutationTaster109 and FATHMM110. 
Each prediction results and score are reported in Table 11.  
Variants SIFT Polyphen2 PROVEAN CADD LRT MutationTaster FATHMM 
c.G345C; p.M115I T B N 16,01 N D T 
c.G481A; p.E161K D D D 33 D D T 
c.C800T; p.T267I D P D 28.5 D D D 
c.G958A; p.G320R D D D 34 D D D 
c.A1110G; p.I370M T B N 9.495 D D D 
c.A1411C; p.T471P D D D 26.9 D D D 
c.A2060C; p.D687A T P D 21.5 D D T 
c.A2137G; p.N713D D D D 25.8 D D D 
c.T2491A; p.C831S T P D 17.12 D D D 
Table 11: Results from prediction tools for DPYD variants. D= Deleterious, T=Tolerated, B= Benign, P=Probably 
Deleterious, N=Neutral, CADD >16 = Deleterious.  
From this analysis, only two DPYD variants (p.M115I and I370M) are deemed to have no impact 
on protein function. However, these computational tools have been optimized on variants associated 
with disease and main rely on evolutionary conservation. This is a hurdle we trying to assess the 
phenotypic consequences of variants that fall on a poorly conserved pharmcogenes111. Nevertheless, 
at the best of our knowledge, to date there are no open tools optimized on pharmacogenes.   
Since several exonic variants may affect splicing mechanisms, DPYD variants were evaluated for a 
possible impact on splicing through HSF web tool112. In Table 12 are reported the results of 
prediction. These data suggest that DPYD variants could have a greater impact on the splicing 
mechanisms than in amino acid point changes. Furthermore, p.M115I is the only variants that seem 
not related to aberrant splicing mechanism and is one of two variants predicted from the previous 
analysis as benign variants. In contrast the other 8 DPYD variants, appear to modify the 
physiological splicing mechanism through modification of non-canonical splicing sites.  















4.8. Molecular visualization 
To understand how DPYD variants may impact the protein function we analyzed 3D protein 
structure with Chimera software113 (Figure 19a, b and c). A human reference structure for this 
protein is missing so we choose the entry 1h7w from the Protein Data Bank (PDB; 
https://www.rcsb.org/) as this sequence shares more than 90% similarity with the Homo sapiens 
DPD. The selected reference (1h7w) is DPYD structure from Sus scrofa (Pig) and its resolution is 
1.9Å. As shown by Figure 19, amino acid substitutions occurs in surface residues of the protein, 
mainly in α-helix or loops motifs far from substrate binding pocket and catalytic site.  
Moreover, understanding impact of these variants on protein activity is a hard task given that each 
variant is distant more than 6Å from cofactors or substrate excluding a possible interaction.  
However, this is only an in silico visualization of variants and thus we cannot rule out a possible 
aberrant mechanism during co-translation folding that may have a strong impact in the protein 
structure and function. Moreover, since many of the missense variants fall on exonic splicing sites, 
the functional impact may be cause by an aberrant splicing mechanism rather than by a single 
amino acid change. 
 
Figure 19a: 3D DPYD monomer protein visualization, green residues represent 3 variants (M115I; E161K and T267I) 
founded in cases cohort 





Figure 19b: 3D DPYD monomer protein visualization, green residues represent 3 variants (G320R; I370M and T471P) 
founded in cases cohort
 
Figure 19c: 3D DPYD monomer protein visualization, green residues represent 3 variants (D687A; N713D and 
C831S) founded in cases cohort 




4.9. Quantification of serum uracil and dihydrouracil concentrations 
Due to the retrospectively nature of this project, only four plasma sample among 9 patients carrying 
a very rare/novel genetic variant on DPYD were available for the measurement of DPD catabolic 
activity. The concentration of uracil (U), dihydrouracil (UH2) and their ratio at baseline make 
possible to estimate the functionality of the enzyme. Metabolites quantification is reported in Table 
13.  
DPYD: NM_000110 






P2 c.G481A p.E161K Exon5 14 94 6,71 
P5 c.A1110G p.I370M Exon 10 10,6 86,4 8,15 
P6 c.A1411C p.T471P Exon12 17,1 101 5,91 
P9 c.T2491A p.C831S Exon 20 11,8 125 10,59 
Table 13: Quantifications of main DPYD’s metabolites, uracil, dihydrouracil and their ratio 
 
According to literature and laboratory’s practice we considered defective DPYD patients to have an 
uracil concentration higher than 16ng/mL. Among these four patients, only proband P6 (c.1411A>C 
p.T471P) showed an altered uracil concentration, whereas P2 had a borderline DPD activity. 
However, from literature emerged that many factors beyond the catabolic activity of DPD may 
influence the uracil, dihydrouracil concentration and their ratio. Thus, we can’t completely rule out 
that the presence of DPYD variants does not hamper the enzyme catabolic activity because as many 
other pharmacokinetic, genetic and related-life style factors might contribute to modify the uracil 
and dihydrouracil plasmatic levels. 
 
4.10. Rare variants, control cohort 
 
To assess whether the rare variants were differentially distributed in patients experiencing severe 
(grade ≥3) toxicity and in patients without, we sequenced a cohort of 106 patients who did not 
experienced severe toxicity in course of FL treatment. Patients were matched with the cohort of 
patients with toxicity by sex, age, primary disease location, treatment regimen and setting.  
Patients characteristics are listed in Table 14. 
In this cohort, 53 (50%) patients are male, 50% are female and they ranged between 26 and 96 years 
old with a average age of 61 years.  
Concerning the primary tumor site 92 (86.8%) patients were affected by CRC, 6 (5.7%) by breast 
cancer, 4 (3.8%) by gastric cancer, 3 (2.8%) by pancreatic and 1 (0.9%) by head-neck tumor.  




Regarding the treatment, only 8 (7.5%) patients were treated in monotherapy with capecitabine, 
while 98 (92.5%) patients were treated with 5-FU based combination regimens. About these 98 
patients, 43 (43.9%) were treated in combination with oxaliplatin, 38 (38.8%) with irinotecan, only 
1 (1%) with platin, 4 (4.1%) with a combination of platin and irinotecan and 12 (12.2%) were 
treated with other combination. Concerning the adverse reactions, 37 (35%) patients did not 
experienced any toxic events, 52 (49%) patients experienced G1 and 17 (16) experienced G2 
toxicities. Sequencing was performed on a MiSeq (Illumina) platform by means of the same gene 
target panel used for the cases cohort. 
  Patients   Treatment 
Characteristic N° (%)   5-FU N° (%) Capecitabine N° (%) 
All 106  87 (82.1%) 19 (17.9%) 
Age     
Mean (range) 61 (26-98)  60 (26-98) 66 (38-83) 
Sex     
Male 53 (50%)  43(49.4%) 9 (47.4%) 
Female 53 (50%)  44 (50.6%) 10 (52.6%) 
Type of cancer     
ColoRectal 92 (86.8%)  77 (88.5%) 15 (78.9%) 
Breast 6 (5.7%)  6 (6.9%) / 
Gastric 4 (3.8%)  1 (1.15%) 3 (15.8%) 
Head-Neck 1 (0,9%)  1 (1.15%) / 
Pancreas 3 (2.8%)  2 (2.3%) 1 (5.3%) 
Treatment      
Monotherapy 8 (7.5%)  / 8 (42.1%) 
Combination: 98 (92.5%)  87 (100%) 11 (57.9%) 
Platin 1 (1%)  / 1 (9.1%) 
Irinotecan 38 (38.8%)  38 (43.7%) / 
Oxaliplatin 43 (43.9%)  36 (41.4%) 7 (63.6%) 
Platin + Irinotecan 4 (4.1%)  4 (4.6%) / 
Others 12 (12.2%)  9 (10.3%) 3 (27.3%) 
Max Grade Toxicity (all)     
G0 37 (35%)  31 (83.8%) 6 (16.2%) 
G1 52 (49%)  43 (82.7%) 9 (17.3%) 
G2 17 (16%)    13 (76.5%) 4 (23.5%) 
Table 14: Control cohort characteristics 
 
 
4.11. Rare variants distribution in the control cohort 
 
From sequencing data of the 106 patients from the control cohort a total of 17,368 variants has 
emerged. This cohort was composed by patients treated with FL-based regimens, wild-type for the 
four DPYD risk variants and at last with absence of severe adverse reactions. In this cohort 755 




unique variants were present and included common polymorphisms, rare and novel variants. 
Moreover, in this cohort most variants fall on UTRs (386; 51.13%). About these, 330 (43.71%) fall 
on 3’UTRs and 56 (7.42%) fall on 5’UTRs. Instead, exonic variants were divided into missense 
(170; 22.52%), synonymous (166; 21.99%), stop gain (4; 0.53%), frameshift (4; 0.53%) and others 
(12; 1.59%) that include in-frame insertion and deletion (Figure 20). Finally, 13 (1.72%) variants 
were detected to influence the splicing sites. However, variant distribution in the control cohort was 
very similar to that reported for the case cohort (see Figure 12). 
 
 
Figure 20: Variants types distribution across 54 target gene in control cohorts 
 
As in the cases cohort, we plotted the type of variants identified on each gene to understand if any 
gene could be enriched with a specific type of variant (Figure 21a, b).  
Except for a few genes, most genes are enriched for variants in the UTR, according to our 
expectations. In contrast to the data emerged from cases set, DPYD gene seemed to be enriched in 





























Figure 21a: Variants distribution per gene in control cohort 
 
Figure 21b: Variants distribution per gene in control cohort 
 
The number of variants per gene may depend on characteristic of gene and sequence. To assess if 
the distribution of variants is influenced by the length of the gene, we normalize the number of 
variants on the length of each gene. To investigate this, in Figure 22 (a, b) we reported in dark blue 
the total number of variants normalized for the gene length and in red the number of exonic variants 
normalized for the coding sequences length, respectively. After normalizing the number of variants 
for the gene’s length, it appears evident that some genes, like CES1 and CYP2A6, are hypervariable 
in both cohorts of patients when compared to other genes, as they have a greater number of variants 
per kbs. These genes seem to have the same trend in the cases and in the control cohort. 






































































































































































































































































Figure 22a: Variants distribution per gene normalized on the gene length in the control cohort 
 
 
Figure 22b: Variants distribution per gene normalized on the gene length in the control cohort 
 
Bearing in mind that a rare variant may have a stronger impact on phenotype than common 
polymorphisms, we investigated the distribution of variants detected according to their minor allele 
frequency (MAF). Among these unique 755 variants, 379 (50.2%) were rare (MAF<0.01), 256 
(33.9%) were very rare variant (MAF<0.001) and finally only 94 (12.4%) were novel variants 
(MAF=0.0) (Figure 23). In the control cohort we observed a depletion of novel variants but no 




















































































































































Figure 23: Variants distribution according to Minor Allele Frequency (MAF) of control cohort 
In addition, we clustered the genes by class like as DPYD, transporters, genes belonging to folate 
pathway, nuclear receptors and others to normalize them on gene’s length as shown previously. 
Genes involved in folate pathway showed a low number of novels, very rare and rare variants per 
kbs when compared with cases cohort group (Figure 24).  
 
Figure 24: Exonic variants distribution per genes classes normalized on the class length in the control cohort 
 
Moreover, in contrast with data emerged from the cases cohort, DPYD does not present novel 
variants and shows a low number of rare and very rare variants per kbs (Figure 24). To assess 
whether this difference may be related to the onset of severe toxicity, we analyzed the distribution 
of rare, very rare and novel DPYD variants in these two cohort through Fisher’s exact test Table 15. 




























very rare variants (P =0.0335) but not with the all novel and rare variants. The absence of 
statistically significant values with all three group may be due to the characteristic of genes where 
exonic sequences results more conserved than UTRs which may result high heterogeneous region. 
Indeed, when we consider only exonic variants, we found a significant enrichment of rare, very rare 
and novel variant of DPYD gene in the cases cohort rather than in control cohort (Table 15, Figure 
25). These data suggest that variants with probably impacting for the onset of toxicity are 
uncommon (MAF<0.01) variants located in the exons of DPYD genes.   
 
ALL (Rare MAF <0.01)   Exonic (Rare MAF <0.01) 
Cohort Total Yes (%) No (%) OR (95% CI) P  Yes (%) No (%) OR (95% CI) P 
Control 106 5 (4.7%) 101 (95.3%) 1    1 (0.9%) 105 (99.1%) 1   










ALL (Very Rare MAF <0.001)   Exonic (Very Rare MAF <0.001) 
Cohort Total Yes (%) No (%) OR (95% CI) P  Yes (%) No (%) OR (95% CI) P 
Control 106 2 (1.9%) 104 (98.1%) 1    1 (0.9%) 105 (99.1%) 1   










ALL (Novel MAF =0)   Exonic (Novel MAF =0) 
Cohort Total Yes (%) No (%) OR (95% CI) P  Yes (%) No (%) OR (95% CI) P 
Control 106 1 (0.9%) 105 (99.1%) 1    0 (0%) 106 (100%) 1   





  6 (5.6%) 102 (94.4%) / 
P = 
0.029 
Table 15: Variants distribution according MAF in the two cohort. 
 
 
Figure 25: Distribution of patients carrying DPYD variants in the two dataset. Each patient has only one variant, and 





































The utility of pre-emptive genotyping test translation as a clinical recommendation remains 
debated, although the pharmacogenetics guidelines for the management of FL-based chemotherapy 
toxicity agree upon the clinical validity of DPYD risk variants.114,115 
We retrospectively evaluated, in a large cohort of patients affected by colorectal cancer, the effect 
of dysfunctional DPYD variants on the risk to develop DLTs related to a FL-based treatment. DLTs 
are defined as grade ≥3 for non-hematological and grade ≥4 for hematological toxicities and lead to 
drug dose reduction or treatment interruption, with potential consequences on the anti-cancer 
efficacy. 
In our study, patients carrying at least one of the four DPYD risk variants (rs3918290; rs55886062; 
rs67376798; rs56038477), were significantly associated to a 2.7-fold increased risk of developing 
DLTs, both acute and total.  
A further step towards a better characterization was achieved using a DPYD GAS model where 
patients are stratified based on their catalytic enzyme activity according to the most updated CPIC 
guidelines. The general trend is maintained after patients’ stratification according to the DPYD 
activity score. Indeed, patients with a GAS of 1.0 (intermediate metabolizer) showed a 10.1-fold 
increased risk to develop DLTs when compared to full metabolizer (GAS = 2.0). On the other hand, 
a weaker association was found between 1.5 GAS carriers and DLTs onset. This result is consistent 
with a milder effect of the variants on the enzyme activity. However, intermediate metabolizer 
(GAS = 1.0) have a stronger association when considering the first three cycles of treatment (OR = 
10.12, 95% CI = 2.55-40.2) rather than entire course of chemotherapy (OR = 7.09 95% CI = 1.69-
29.65). In opposite way, only when considering the entire course of chemotherapy, the 1.5 DPYD 
carriers display an increased risk to develop DLTs (OR = 2.08, 95% CI =1.02-4.27). 
Moreover, to better understand the toxicity profile in relation to the GAS model, we evaluated the 
distribution of toxicity events among the three GAS group. We considered separately grade 3 and 
grade 4 toxicities, without distinguishing between hematological and non-hematological adverse 
reactions. Patients with a 1.0 GAS was enriched for grade 4 toxicities, which was not maintained 
when considering patients with a 1.5 GAS which showed an increased onset of grade 3 toxicities. 
These results suggested that a lower DPYD activity score is strictly related to a more severe and 
acute toxicity onset while an intermediate activity is strictly related to a more mild and delayed 
toxicity. 




One of the major causes of poorly widespread of pharmacogenomics diagnostic test in clinical 
practice lies in the lack of information on the usefulness and on economic consequences. Indeed, 
pharmacogenomics test can help to set the best therapy and at same time decrease the cost of 
treatments. Our study reports, for the first time, that patients’ genotypes for the four DPYD risk 
variants allow to predict those patients with significant higher chemotherapy-related toxicity 
management costs, among subjects treated with fluoropyrimidines-based treatment. Moreover, 
patients carrying at least one of the four DPYD risk variants have an increased risk to develop 
toxicity which are associated with a higher toxicity management costs compared with noncarriers, 
especially when requiring hospitalization. Indeed, hospitalization result to be the most expensive 
intervention for management of adverse reactions.  
By stratifying patients according to the DPYD gene activity score, toxicity management cost is 
inversely proportional to the GAS. The highest management cost was associated with rs3918290 
(DPYD*2A) carriers, and the lowest was associated with carriers of rs67376798 (DPYD c.2846) 
and rs56038477 (DPYD Hap-B3). Once again in our cohort, the poor metabolizer has been 
associated with early severe toxicity and a high toxicity management cost, while patients with a 
mild impact variant exhibit accumulation toxicity and management cost of lower toxicity. 
These finding support the utility of pharmacogenomics classification according to DPYD genotype 
especially if considering that the costs for genotyping will decrease soon. 
In the present study, fluoropyrimidines were administered with different combination regimens 
because monotherapy is not the standard therapy for patients with CRC. However, our analysis 
allowed a direct correlation of Fl monotherapy management costs with the costs associated with the 
combination with other chemotherapy drugs. Indeed, the mean cost per patient was highest for 
patients treated with a combination of fluoropyrimidine with oxaliplatin. This is due not only to the 
occurrence of severe neuropathy, but also to a general increase in the occurrence of hematological 
and gastrointestinal toxicities.  
DPYD wild-type patients treated with a combination of fluoropyrimidine and oxaliplatin had a 
mean toxicity management cost that was 4-fold higher than wild-type patients treated with 
fluoropyrimidine monotherapy. This analysis demonstrates that DPYD variants may affect the cost 
of toxicity management in monotherapy treatment with FL as well as may affect the cost of 
toxicities in combination regimens. 
Despite the reported results a great number of toxic events are still not explained. Indeed, the 4 
DPYD risk genetic variants allow to predict a limited number of all adverse events. 
Pre-treatment phenotyping of DPD activity through measurement of DH2/U metabolite in plasma, 
by monitoring DPD activity in peripheral blood mononuclear cells (PBMCs), that remain the gold 




standard, and other methods can be helpful tools to predict toxicity and efficacy of FL.49,116–119 
However, this phenotypic approach is not easily applicable in the routine clinical practice.49 One of 
the major limitations is the lack of fully validated or standardized methods. Furthermore, 
genotyping methods are easier, faster and very less expensive than phenotyping methods.49 
In contrast to SNPs genotyping methods, NGS approach on DPYD were used and allowed the 
identification of new deleterious variants as well as common SNPs.120 Furthermore, recent analysis 
from different public human genetic variants data sets highlight that deleterious variants have lower 
allele frequencies than neutral variants due to negative selection.39,98 However, this analysis was 
performed on a very large and heterogeneous patients database, indeed patients in these databases 
result affected by difference human disease or disorders as well as cancer, neurogenerative disease, 
obesity and others. 
Here, we reported for the first time rare and common variants in 54 pharmacogenes involved in 5-
FU/Capecitabine pathway detoxification in patients affected by severe adverse reaction (G≥3). 
In the first place we analyzed a group of patients with extreme toxicity to highlight possible 
causative variants. From sequencing data of 108 patients affected by extreme toxicity phenotype 
emerged a total of 19,960 variants with an average of 184 variants per patient, 961 were unique 
variants and included common polymorphisms, rare and novel variants. 
Keeping in mind that we aimed to identify rare variants which may have a stronger impact on 
protein function, we clustered these unique 961 variants according Minor Allele Frequency (MAF) 
of European population.39,98 From this analysis, 434 (45.2%) are rare with a MAF<0.01, 273 
(28.4%) are very rare variants (MAF<0.001) and 176 (18.3%) are novel variants. 
We supposed that the number of variants per gene could reflect a difference in the role of these 
genes in the onset of toxicity. However, many other factors can influence the number of variants 
including gene length, evolutionary gene conservation and the length of untranslated regions 
(UTRs). 
To exclude these, we normalized the number of variants in each gene on the gene length. Due the 
fact that an exonic variants may have a bigger impact on the protein function than variants in UTRs, 
the same analysis was performed considering only exonic variants and normalizing for the coding 
sequences (CDS) length. Genes like CES1 and CYP2A6 appear hypervariable compared to others 
due to the greater number of variants per kbs in both analyses. Furthermore, the number of variants 
per gene does not seem to be influenced by the length of UTRs or genes. Moreover, to study the 
distribution of rare, novel variants we clustered genes by class like as DPYD, transporters, genes 
belonging to folate pathway, nuclear receptors and others. DPYD and genes involved in folate 
pathway showed a relatively higher number of novels, very rare and rare variants (Figure 13). 




We subsequently focused our attention on the major candidate gene in the development of FL-
related toxicity, i.e. DPYD. Thanks to NGS, we highlighted in the 108 patients with severe toxicity, 
three very rare missense (c.G345C, p.M115I; c.A2060C p.D687A and c.A2137G, p.N713D) 
variants (MAF < 0.001) and six singleton missense (c.A110G, p.D37G; c.G481A, p.E161K; 
c.C800T, p.T267I; c.G958A, p.G320R; c.A1110G, p.I370M; c.C1579T, p.P527S) variants on 
DPYD gene which may be causative of FL toxicity (Table 10). All DPYD variants were confirmed 
by Sanger sequencing. About these variants, we evaluated the possible impact on the protein. To do 
this, we used seven different prediction tools and, based on the provided scores, 7 out of 9 variants 
(p.D687A, p.N713D, p.D37G, p.E161K, p.T267I, p.G320R, p.P527S) seem to be deleterious for the 
protein function. However, these prediction tools have been not optimized on variants which fall on 
pharmcogenes, as DPYD.111,121 Indeed, the prediction tools commonly used to assess the role of the 
big amount of variants emerged from NGS studies are highly influenced by the conservation score 
of the gene or better of the nucleotide. The conservation score measures the evolutionary 
conservation of the gene or of the single nucleotide/amino acid through the alignment of multiple 
sequences with paralogs and orthologs genes. Highly conserved positions are often indicative of 
their structural and/or functional importance. It is easy to understand that this score can be very 
helpful in genes highly conserved but usually found mutated in human diseases like cancers. 
However, to the best of our knowledge, to date only two works developed specific prediction tools 
for pharmacogenomics variants that unfortunately are not yet available.111,121 
Moreover, since these missense variants fall on exonic splicing sites we evaluated a possible impact 
on splicing. HSF web tool suggested that DPYD variants could have a greater impact on the splicing 
mechanisms rather than in amino acid point changes.112 
To better understand how this 9 variants can be deleterious, we analyzed 3D protein structure with 
UCSF Chimera.113 Amino acid substitutions occur in surface residues of the protein, mainly in α-
helix or loops motifs far from substrate binding pocket and catalytic site. Moreover, understanding 
impact of these variants on protein activity is a hard task given that this is only an in silico 
visualization of variants and thus we cannot rule out a possible aberrant mechanism during co-
translation folding that may have a strong impact in the protein structure and function. Moreover, 
since many of the missense variants fall on exonic splicing sites, the functional impact may be 
caused by an aberrant splicing mechanism rather than by a single amino acid change. 
Thanks to the collaboration with Dr Hilde Rosing of Department of Pharmacy and Pharmacology in 
The Netherlands Cancer Institute, we evaluated the DPD activity by measuring plasma pretreatment 
concentration of uracil (U) and dihydrouracil (UH2) through a validated LC-MS/MS method. 
According to literature and laboratory’s practice we considered defective DPYD patients when 




uracil concentration is higher  than 16ng/mL.122 However, due to the retrospective nature of this 
project, only four plasma samples among 9 patients are available for measurement of DPD activity. 
About these four patients, patient carrying p.T471P variants shows an altered uracil concentration 
whereas patient carrying p.E161K variant shows a borderline activity. The same trend was observed 
when we considered UH2:U ratio. Thanks to phenotyping test, we are confident that the p.T471P 
DPYD mutation is the cause of neutropenia G3 that affect this patient during the first treatment 
cycle. However, gender and other genetic factors may influence the uracil, dihydrouracil 
concentration and consequently their ratio (UH2:U).116 
More than 90% of the variants present in the pharmacogenes are rare variants, which represent the 
30-40% of functional variability in pharmacogenes.39,98-100 Due to the high human interindividual 
heterogeneity we cannot exclude that these data are related to the investigated phenotype rather than 
human heterogeneity. In order to exclude that, we compared the data of DPYD wild type patients 
that experienced adverse events (the case cohort) with those of a control cohort. Control cohort was 
composed by 106 patients who did not experienced severe toxicity (G<3). 
From NGS data, from control cohort emerged a total of 17,368 variants with an average of 163 
variants per patients. About these 17,368 variants,755 are unique. 
In control cohort we observe a depletion of novel variants (p value =0.001) which may indicate a 
functional impact of novel variants in the onset of adverse reactions. 
Clustering the genes by class and normalizing for the CDS length as previously done for the case 
cohort, we showed a significant (low number of rare, very rare and novel exonic variants per kbs 
(Figure 25) (P =0.0187, P =0.0187, P =0.0291, respectively). DPYD did not present novel variants 
in 106 patients of control cohort, however, emerged only a very rare missense (c.G1117A; p.V373I; 
rs772906420) variant. 
Despite some limitations such as the heterogeneity of the patients, of the treatment regimens, of the 
sites of the primary tumor in this study, we have highlighted as common and new variants in the 
5FU/Capecitabine detoxification pathway may affect the development of severe toxicity. However, 
given the heterogeneity of treatment regimens and co-treatments it is impossible to discriminate the 
effect of individual drugs in the development of severe adverse events. 
Moreover, the retrospective nature of the study prevented the access to suitable biological material 
to allow the assessment of the functional impact of all these variants. Furthermore, this work of 
thesis focused only on a preliminary analysis of the data almost exclusively limited to the results 
obtained for the DPYD gene. However, we are already working on the analysis of the bulk of data 
deriving from the entire panel of 54 genes through focused bioinformatics analysis. Finally, due to 
the huge number of rare variants and the difficulty to evaluate their functional impact, we will need 




large prospective studies to validate the role of these rare variants before they can be used in clinical 
practice. 
Concluding, we showed how pre-emptive DPYD genotype test could be helpful in reducing the 
number of adverse reaction and at the same time allow to reduce the management cost for severe 
toxicities in monotherapy treatment but also in combination regimens. Furthermore, in this work, 
we showed how novel variants in 5-FU/capecitabine pathway detoxification can explain the 
development of severe toxicity phenotype in all those patients that are wild type for the well-know 4 
DPYD risk variants.  
Despite the recent efforts of precision medicine in optimizing treatments on each patient, to date 
translating the genetic information of each patient into a therapeutic indication remains a hard and 
time-consuming task. Indeed, further efforts are needed to identify new markers of severe toxicity 
development that in the future can be used in clinical practice. 








To validate the clinical value of the pre-emptive DPYD test, from an already existing database and 
biobank of patients with cancer we selected a retrospective multicenter population of 763 patients. 
Eligibility criteria we applied were: (i) histologically confirmed diagnosis of colorectal cancer 
(CRC), (ii) fluoropyrimidine‐based treatment, (iii) availability of a peripheral blood sample, and 
(iv) signed informed consent approved by the local Ethical Committee.  
Secondly, to assess the relationship between DPYD genotype and management-related cost we 
selected a population of 550 patients affected by CRC with FL-based therapy (Figure 25). 
Eventually, to investigate the role of rare and novel germline variants in the toxicity onset, we 
selected a subpopulation of 120 DPYD wild-type patients (Figure 25). This subpopulation is 
characterized by: (i) fluoropyrimidine-based treatment, (ii) experience of extreme toxicity (grade 3 
to 5), (iii) absence of 4 risk variants, (iv) availability of a peripheral blood sample, and (v) signed 
informed consent approved by the local Ethical Committee.  
 
Figure 25: Study design 




6.2. Data collection 
 
The baseline clinical and demographic characteristics were retrieved for each patient, which 
include: chemotherapy schedule, dosage, deviation from the treatment schedule (i.e., drug dose 
reduction, delays, or early treatment interruption), and the complete list of treatment‐related toxic 
events at each chemotherapy cycle, until drug discontinuation for any reason. Clinical and toxicity 
data for these patients were collected by the Experimental and Clinical Pharmacology Unit of 
CRO‐Aviano. The causality of the toxic events was assessed by the physician at the time of 
occurrence, and only the chemotherapy‐related events were recorded. All the toxic events were 
graded according to NCI‐CTC for Adverse Events version 5.0. 
 
6.3. Toxicity management cost 
 
The cost of each toxicity event develop during treatment was listed based on three expert clinical 
oncologists from CRO-Aviano. Only the chemotherapy-related toxicity events were recorded by 
clinicians at the time of occurrence at each treatment cycle. The total cost was calculated as the sum 
of whole cost management occurring during each toxicity events, limited to the first 12 cycles of 
treatment. However, some patients were enrolled in different parts of Italy, most of them were 
recruited in Friuli Venezia Giulia Region. The Italian Public Heat Care System is regulated at 
regional level, so for this reason the analysis cost derived from the following: (i) the Health Agency 
of the Friuli Venezia Giulia Region (http://www.egas.sanita.fvg.it/) and (ii) the current version of 
the Friuli Venezia Giulia Regional Health System website. 
The analysis covers whole cost related to clinical management including drugs, laboratory and 
instrumental examinations, nurses, and physicians for the needed time of hospitalization.  The 
remain indirect costs such as productivity loss, transport, accommodation and others were not 
considered in this study. 
 
6.4. DPYD Genotyping 
 
DNAwas extracted with BioRobot EZ1and EZ1 DNA Blood Kit (Qiagen, Hilden, Germany) 
according to manufactures’ instruction. Genotype was assessed for the four DPYD risk variants 
(c.1905+1G>C, *2A; c.1679T>G, *13; c.2846A>T, D949V and c.1236G>A, HapB3) by 
Pyrosequencing or Real-Time PCR and confirmed with Sanger sequencing. 




In Table 16 are listed the primer sequence used for the amplification and sequencing of the four risk 
variants.  
DPYD: NM_000110 

































Pyrosequencing is a sequencing-by-synthesis technique based on the detection of light. The first 
step consists in the amplification of DNA template with a biotinylated primer. Then, using 
streptavidin-coated magnetic beads the template is immobilize on the bead’s surface. With a second 
primer the complementary strand is synthesize one base pair at a time. Each base incorporated 
releases a pyrophosphate (PPi) molecule because of nucleotide chain elongation. The enzyme ATP 
sulfurylase converts PPi to ATP in the presence of adenosine 5’ phosphosulfate (APS). The ATP 
generated acts like as substrate for the enzyme luciferase which converts luceferin to oxyluciferin, 
thus generating light at a wavelength of 560 nm. The intensity of light emitted is proportional to the 
amount of ATP. At the end of each cycle, the unincorporated dNTPs and ATP are degraded by the 
apyrase.    




For the amplification of DNA target regions, the “AmpliTaq Gold™ DNA Polymerase with Gold 
Buffer and MgCl2kit” (Applied Biosystem Inc., Carlsbad, CA, USA) has been used, according to 
the mix reported in Table 17. 
Reagent Volume (µl) FinalConcentrazion 
DNA 1,5  
Buffer 10X 5 1X 
dNTPs[25mM] 0,25 0,125mM 
MgCl2 [25mM] 5 2,5mM 
Primer F [100µM] 0,1 0,2µM 
Primer R [100µM] 0,1 0,2µM 





Table 17: Pyrosequencing mix composition 
The thermal cycle used for DNA amplification was:  
• Polymerase activation at 95 °C per 10’ 
• 35 cycles of: 
- Denaturation at 95 °C for 30” 
- Annealing at 56 °C for 30” 
- Extension at 72 °C for 1’ 
• Final elongation at 72 °C for 5’ 
Reagents used for pyrosequencing was magnetic beads (3µl) are load on the disk and mixed with 
10µl of sample on PyroMark Q48 Autoprep (Qiagen, Hilden, Germany). 2 µl of sequencing primers 
(4µM) are mix with an 8µl of annealing buffer for a final concentration of 800nM and are loaded in 
injector catrigdes. The four dNTPs, binding buffer (5µl for each sample), substrate, enzyme and 
apyrase are load in automatic injectors catrigdes according to manufactures’ instruction. 
 
6.4.2. Allelic discrimination in real-time PCR by fluorescent-labeled probes 
 
Real-Time PCR (RT-PCR or qPCR) is a technique that allows the amplification and the 
simultaneous quantification of target DNA. Through a pair of sequence-specific fluorescent probe 
that hybridize with the target sequence, this technique allows to discriminate patient’s genotype. In 
these analyses we used a dual label TaqMan probes (FAM and VIC) that emit respectively at 
517nm and 551nm. The detection is allowed by using the thermocycler 7500Real-Time PCR 
System (Applied Biosystem Inc., Carlsbad, CA, USA). 
Each sample was analysed according to mix reported in Table 18 with the follow thermal cycle: 





• Polymerase activation at 95 °C per 10’ 
• 55 cycles of: 
- Denaturation at 92 °C for 15’’ 
- Annealing/Extension at 60 °C for 1’ 
Reagent Volume (µl) FinalConcentrazion 
PCR product 1,5  
MasterMix 2X 10 1X 
AssayMix 20X 1 1X 
H2O 7,5  
Total 20  
Table 18: Real-Time mix composition 
For the DPYD c.2846 variants assay, primers and probes are reported in Table 19. 
HapB3 was screening according to the commercial TaqMan® SNP Genotyping Assay (Assay ID: 
C__25596099_30) (Thermo Fisher Scientific, Wilmington, DE, USA). No information about 
sequences of primers and probes have been released by the company. 
DPYD: NM_000110 




Probe Sequence: 5’→ 3’ 
2846 
 VIC-TGGCTATGATTGATGAAGAA-MGB 
  6-FAM-TGGCTATGATTGTTGAAGAA-MGB 
Table 19: Primers and probes for RT-PCR 
6.4.3. Sanger Sequencing for DPYD *2A; *13; c.2846A>T, and HapB3 variants validation 
 
Sanger sequencing was adopted to confirm the presence of four risk variants previously highlight by 
Pyrosequencing and Real-Time PCR.PCR was used to amplified DNA following the reported 
thermal cycle. 
c.1905+1G>C and c.1679T>G:  
• Polymerase activation at 95 °C per 10’ 
• 35 cycles of: 
- Denaturation at 95 °C for 30” 
- Annealing at 56 °C for 30” 
- Extension at 72 °C for 1’ 
• Final elongation at 72 °C for 5’ 





• Polymerase activation at 95 °C per 10’ 
• 35 cycles of: 
- Denaturation at 95 °C for 30” 
- Annealing at 63 °C for 30” 
- Extension at 72 °C for 30’’ 
• Final elongation at 72 °C for 7’ 
c.1236G>A: 
• Polymerase activation at 95 °C per 10’ 
• 35 cycles of: 
- Denaturation at 95 °C for 30” 
- Annealing at 58 °C for 30” 
- Extension at 72 °C for 30’’ 
• Final elongation at 72 °C for 10’ 
The PCR product have been subjected to electrophoresis on agarose gel at 1% in 1X TBE buffer. 
For the Sanger sequencing, the amplified were firstly purify with Diffinity RapidTip®2 (Sigma-
Aldrich, Inc., Milwaukee, WI, USA), then were prepared through a three-step method. The first step 
consists in labelling amplified DNA whit the fluorescent nucleotide. A mix with polymerase, 
primer, dNTPs and label ddNTPs from “BigDye® Terminator v3.1 Cycle Sequencing Kit” (Applied 
Biosystem Inc., Carlsbad, CA, USA) are used like reporter in Table 20. Label ddNTPs lack the 3’-
OH group of dNTPs that is essential for polymerase-mediated strand elongation in a PCR. Thermal 
cycle: 
• Polymerase activation at 96 °C per 1’ 
• 30 cycles of: 
- Denaturation at 96 °C for 1’  
- Annealing at 50 °C for 30” 
- Extension at 60 °C for 2’ 
Reagent Volume (µl) Final Concentrazion 
PCR product 2  
Buffer 1.2  
BigDye Terminator3.1 1  
Primer [3,3µM] 1 0,3µM 
H2O 4,8  
Total 10  
Table 20: Label mix for Sanger sequencing 
 




The labeled fragments are purified through precipitation. 10µL of label DNA was mixed with 75µL 
of magnesium ethanolate and incubated for 10’ at RT. Then it was centrifuged at 13000G for 15’ at 
4 °C to allow the precipitation of DNA. Eventually, the supernatant was promptly discarded, and 
the DNA pellet was resuspended in 15µL of HiDi™ Formamide (Applied Biosystem Inc., Carlsbad, 
CA, USA). Isolated DNA was then denatured at 96 °C for 2’ and loaded in the automatic DNA 
sequencing. 
Finally, the automatic DNA sequencing (AB3130xl Applied Biosystem Inc., Carlsbad, CA, USA) 
was used to separate electrophoretically the DNA fragment. The emitted fluorescent light is 
revealed, and sequencing data are transferred tothe instrument computer that, by an algorithm, 
converts them into electropherograms. To display the electropherograms the “FinchTV” (Geispiza) 
program was used. 
 
6.5. Selection of candidate genes for Next Generation Sequencing 
 
Based on PubMed database (https://www.ncbi.nlm.nih.gov/pubmed/) and PharmGKB 
(https://www.pharmgkb.org/), we selected 54 genes including DPYD and its regulators regions, 
genes involved in tegafur and capecitabine pathways, transporters and nuclear receptors related to 























6.6. Targeted Next Generation Sequencing 
 
To perform NGS analysis, we designed a hybridization based custom NimbleGenSeqCap EZ 
Choice Library (Roche, Inc., Madison, WI, USA) to target the 5’ and 3’ UTR and coding sequence 
of genes. 3 kb of genomic sequence flanking at the 5′UTR ends of DPYD, MTHFR and TYMS gene 
was included, accounting for a total of 186.535 bp. 
Libraries were constructed according to the NimbleGen SeqCap EZ Library SR User’s Guide v3.0 
(Roche, Inc. Madison, WI, USA) (Figure 26). Pooled libraries were loaded according to the DNA 
Truseq protocol (Illumina, Inc., San Diego, CA, USA). 
 
Figure 26: DNA library preparation workflow 
Briefly, genomic DNA from blood was firstly purified using Agencourt AMPure XP Beads 
(Beckman Coulter, Brea, California, USA), then the quality was assessed through NanoDrop 
(Thermo Fisher Scientific, Wilmington, DE, USA) and Quantus Fluorometer (Promega, Madison, 
Wisconsin, USA). 
100 ng of each samples were diluted into 35µL and fragmented with eight different restriction 
enzymes for 15’ at 37 °C to obtain fragments of approximately 200bp following Table 22.  
 Reagents  Volume(µL) 
gDNA 35 
KAPA Frag Buffer (10X) 5 
KAPA FragEnzyme 10 
Total 50 
Table 22: Fragmentation mix 
Then, DNAs were subjected to three enzymatic steps: end repair, A-tailing and ligation to Illumina 
paired-end indexed adapters (Table 23 and Table 24). 
 





KAPA End Repair & A-tailing Buffer 7 
KAPA End Repair & A-tailing Enzyme Mix 3 
Total 10 
Table 23: End repair and A-tailing mix 
 
Reagents Volume(µL) 
PCR-grade water 5 
KAPA Ligation Buffer 30 
KAPA DNA Ligase 10 
Total 45 
Table 24: Index ligation mix 
Once the DNA libraries were indexed, a double-sided selection was performed to obtain fragments 
of approximately 300-350bp, then they were PCR-amplified according to the follow thermal cycles: 
• Activation of polymerase at 98 °C for 45’’ 
• 12 amplification cycles split in:  
- Denaturisation at 98 °C for 15’’ 
- Annealing at 60 °C per 30’’ 
- Extension at 72 °C per 30’’ 
• Final elongation at 72 °C per 1’ 
The amplified fragments were quantified by NanoDrop (Thermo Fisher Scientific) and Quantus 
(Promega). To assess the fragments’ length distribution, each library was analyzed through 2200 
High Sensitivity TapeStation (Agilent Technologies, Santa Clara, CA, USA) according to 
manufacturer’s instruction (Figure 27).   
Figure 27: TapeStation workflow 
45ng of amplified DNA from each sample were pooled, then were in-solution hybridizated to a 
custom NimbleGenSeqCap EZ Choice Library (Roche, Inc.) of complementary oligonucleotide 
DNA baits. After washing, the captured fragments were amplified following this thermal cycle: 
• Activation of polymerase at 98 °C for 45’’ 
• 7 amplification cycles split in:  
- Denaturation at 98 °C for 15’’ 




- Annealing at 60 °C per 30’’ 
- Extension at 72 °C per 30’’ 
• Final elongation at 72 °C per 1’ 
Then the pooled-libraries were sent for sequencing to generate 2 × 150 bp paired-end reads using 
MiSeq platform (Illumina, Inc.). The resulting fastQ files were analyzed using an in-house-
developed pipeline described below. 
 
6.7. Bioinformatic analysis 
 
FASTQ sequencing reads were initially trimmed using trimmomatic-0.36 and assessed in terms of 
sequencing quality, those falling below the required quality threshold were excluded from 
subsequent analyses.123 Then, the FASTQ sequencing trimmed reads were mapped to human 
reference genome (UCSC hg19 NCBI build 37.1) assembled using Burrows-Wheeler Aligner 
(BWA).124 The Bam files obtained were sorted, indexed and visualized by Integrative Genomics 
Viewer (IGV).125 
Local realignment around indels and PCR duplicate removal were performed by Genome Analysis 
Toolkit (GATK) (Broad Institute, Cambridge, MA)mand picard MarkDuplicates 
(http://broadinstitute.github.io/picard).126,127 Single nucleotide variations and indels were called 
through VarScan2.128 Variant effect prediction was done using Annovar and annotated using 
population based annotations such as dbSNP, 1000 Genomes Project, NHLBI Exome Project 
(ESP6500) (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA 
(http://evs.gs.washington.edu/EVS/)) and Exome Aggregation Consortium (ExAC, 
http://exac.broadinstitute.org/).95,129,130  
 
6.8. In silico functional prediction tools 
 
To evaluate the functional impact of exonic variants we used five different prediction algorithms 
that are SIFT, PolyPhen, PROVEAN, CADD, LRT, MutationTaster and FATHMM.104-110 In 
addition, for variants that fall near the exon junctions we integrated the results from HSF.112 HSF 
combine different tools and algorithms that allow to study canonical as well as non-canonical 
splicing regions including: matrices for SR protein from ESEfinder, exonic and intronic sequence 
region from RESCUE-ESE hexamers, algorithms to find PESE and PESS octamers motif identified 
by Zhang and Chasin, exon and intron-identity element (EIE and IIE) defined by Zhang and 




colleagues, ESR sequence identify by Goren and a new algorithms for silencer sequences defined 
by Sironi and co-workers and ESS decamers.131-137 
 
6.9. Sanger Sequencing to validate the DPYD variants detected by NGS 
 
Sanger sequencing was adopted to confirm the presence of variants previously highlight by NGS.  
All primers were designed through Primer3Plus and evaluated for the specificity by NCBI 
BLASTn.138,139 In Table 25 are present the primer sequence used for the amplification and 
sequencing.  
For the amplification has been used the “AmpliTaq Gold™ DNA Polymerase with Gold Buffer and 
MgCl2kit” (Applied Biosystem Inc., Carlsbad, CA, USA Inc., Carlsbad, CA, USA) following the 
same procedure previously reported in Table 17. 
Each PCR reaction was submitted to the follow thermal cycle: 
• Activation of polymerase at 95 °C for 10’ 
• 35 amplification cycles of:  
- Denaturisation at 95 °C per 30’’ 
- Annealing ±4 °C at 60 °C per 30’’ 
- Extension at 72 °C per 30” 















Variants Primers Sequence: 5’→ 3’  








































Table 25: Primers for variants control through Sanger sequencing 
 
6.10. Molecular visualization  
 
To visualize DPYD 3D protein we use Chimera software.113 Protein structure (1h7w) from Sus 
scrofa (Pig) was downloaded from the Protein Data Bank (PDB). Protein structure was at 1.9Å 
resolution.  
 
6.11. Quantification of serum uracil and dihydrouracil concentrations 
 
Thanks to the collaboration with Dr Hilde Rosing of Department of Pharmacy and Pharmacology in 
The Netherlands Cancer Institute, we were able to estimate DPD activity by measuring plasma 
pretreatment concentration of uracil (U) and dihydrouracil (UH2) through a validated LC-MS/MS 
analysis122. Briefly, after protein precipitation, clear supernatants were collected and separated with 
a short chromatographic run with Acquity UPLC system (Waters, Milford, MA, USA) coupled to a 
QTrap 5500 triple quadrupole spectrometer (Sciex, Framingham, MA, USA).  
According to laboratory practice the threshold to identify deficient DPD enzyme was put at 
16ng/ml.140   
 




6.12. Statistical analysis 
 
The association between the DPYD genotype and the risk to develop DLT was evaluated grouping 
patients according to the presence of at least one risk variant in the 4-SNP panel and accordingly to 
GAS model. SNPs frequency were compared with those reported for Caucasian population in 
dbSNP (https://www.ncbi.nlm.nih.gov/SNP/) and then tested for deviation from Hardy-Weinberg 
equilibrium. The association between patients carrying DPYD risk allele and toxicity occurrence 
was estimated through an unconditional logistic regression model, adjusted for gender, age, 
chemotherapy scheme and radiotherapy exposure. Odds ratio (OR) and 95% confidence interval 
(CI) were calculated and the statistical significance was set at P <0.05 (two-sided). 
For the pharmacoeconomics analysis, patients were stratified into non-carrier group (patients 
without DPYD variants) and carrier group (patients with at least one DPYD risk variant, rs3918290, 
rs55886062, rs67376798 and rs56038477). Moreover, patients were categorized according to the 
DPYD gene activity score (GAS).  
For the statistical analysis we applied general linear models with γ distribution and log-link 
function. Management cost was predicted on a model equation that included physiological factors 
such as sex, age, and treatment factors like as setting (adjuvant/metastatic), number of cycles, and 
chemotherapy regimen. The statistical difference between mean toxicity management costs in each 
genotype group or chemotherapy regimen was evaluated by ANOVA. 
Assessment of association between patients with DPYD variants and hospitalization or toxicity 
occurrence was estimated through an unconditional logistic regression model, adjusted for sex, age, 
setting (adjuvant/metastatic), number of cycles, and chemotherapy scheme. 
The association between DPYD genotype and hospitalization was tested by Fisher’s exact test. OR 
and 95% CI were computed, and statistical significance was set at P < 0.05. Using the χ2 test we 
assessed the statistically significant differences in hospitalization rates within patients undergoing 
different chemotherapy regimens. 
Difference in variants distribution of rare, very rare and novel variants on DPYD genes between the 
cases and control cohort were analyzed using Fisher’s exact test, statistical significance was set at P 
< 0.05.
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